| Hits from PDB |
Structure Title |
EC number |
| 6V6U | CRYSTAL STRUCTURE OF RHOA-GDP WITH NOVEL SWITCH I CONFORMATION | 3.6.5.2 |
| 6V6V | CRYSTAL STRUCTURE OF ONCOGENIC RHOA MUTANT G14V COMPLEXED WITH GDP | 3.6.5.2 |
| 6V6Y | CRYSTAL STRUCTURE OF T. THERMOPHILUS METHYLENETETRAHYDROFOLATE DEHYDROGENASE (MTHFD) | 1.5.1.5 3.5.4.9 |
| 6V70 | CRYSTAL STRUCTURE OF METALLO BETA LACTAMASE FROM HIRSCHIA BALTICA WITH CADMIUM IN THE ACTIVE SITE | 3.5.2.6 |
| 6V71 | CRYSTAL STRUCTURE OF METALLO BETA LACTAMASE FROM HIRSCHIA BALTICA WITH NITRATE IN THE ACTIVE SITE | 3.5.2.6 |
| 6V7C | HUMAN ARGINASE1 COMPLEXED WITH BICYCLIC INHIBITOR COMPOUND 3 | 3.5.3.1 |
| 6V7D | HUMAN ARGINASE1 COMPLEXED WITH BICYCLIC INHIBITOR COMPOUND 10 | 3.5.3.1 |
| 6V7E | HUMAN ARGINASE1 COMPLEXED WITH BICYCLIC INHIBITOR COMPOUND 12 | 3.5.3.1 |
| 6V7F | HUMAN ARGINASE1 COMPLEXED WITH BICYCLIC INHIBITOR COMPOUND 13 | 3.5.3.1 |
| 6V7H | STRUCTURE OF CTX-M-14 BOUND TO VABORBACTAM AT 1.0 A | 3.5.2.6 |
| 6V7I | STRUCTURE OF KPC-2 BOUND TO VABORBACTAM AT 1.25 A | 3.5.2.6 |
| 6V7N | CRYSTAL STRUCTURE OF A HUMAN LYSOSOME RESIDENT GLYCOPROTEIN, LYSOSOMAL ACID LIPASE, AND ITS IMPLICATIONS IN CHOLESTERYL ESTER STORAGE DISEASE (CESD) | 3.1.1.13 |
| 6V7T | CRYSTAL STRUCTURE OF CTX-M-14 E166A/D240G BETA-LACTAMASE IN COMPLEX WITH CEFTAZIDIME | 3.5.2.6 |
| 6V83 | CRYSTAL STRUCTURE OF CTX-M-14 E166A/P167S/D240G BETA-LACTAMASE IN COMPLEX WITH CEFTAZIDIME-1 | 3.5.2.6 |
| 6V8V | CRYSTAL STRUCTURE OF CTX-M-14 E166A/P167S/D240G BETA-LACTAMASE IN COMPLEX WITH CEFTAZIDIME-2 | 3.5.2.6 |
| 6V94 | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6V9F | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6V9J | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6V9L | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6V9M | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6V9N | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6V9O | EXPANDING THE CHEMICAL LANDSCAPE OF SOS1 ACTIVATORS USING FRAGMENT BASED METHODS | 3.6.5.2 |
| 6VBC | CRYSTAL STRUCTURE OF TRANSPEPTIDASE DOMAIN OF PBP2 FROM NEISSERIA GONORRHOEAE CEPHALOSPORIN-RESISTANT STRAIN H041 | 3.4.16.4 |
| 6VBD | CRYSTAL STRUCTURE OF TRANSPEPTIDASE DOMAIN OF PBP2 FROM NEISSERIA GONORRHOEAE CEPHALOSPORIN-RESISTANT STRAIN H041 ACYLATED BY CEFTRIAXONE | 3.4.16.4 |
| 6VBH | HUMAN XPG ENDONUCLEASE CATALYTIC DOMAIN | 3.1 |
| 6VBI | CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH A NON-COMPETITIVE INHIBITOR | 3.1.4.35 |
| 6VBL | CRYSTAL STRUCTURE OF THE TRANSPEPTIDASE DOMAIN OF PBP2 FROM THE NEISSERIA GONORRHOEAE CEPHALOSPORIN DECREASED SUSCEPTIBILITY STRAIN 35/02 | 3.4.16.4 |
| 6VBM | CRYSTAL STRUCTURE OF A S310A MUTANT OF PBP2 FROM NEISSERIA GONORRHOEAE | 3.4.16.4 |
| 6VCE | HIV-1 WILD TYPE PROTEASE WITH GRL-026-18A, A CROWN-LIKE TETRAHYDROPYRANOTETRAHYDROFURAN WITH A BRIDGED METHYLENE GROUP AS A P2 LIGAND | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6VCN | CRYSTAL STRUCTURE OF E.COLI RPPH IN COMPLEX WITH PPCPG | 3.6.1 |
| 6VCO | CRYSTAL STRUCTURE OF E.COLI RPPH IN COMPLEX WITH PPCPA | 3.6.1 |
| 6VCP | CRYSTAL STRUCTURE OF E.COLI RPPH IN COMPLEX WITH UTP | 3.6.1 |
| 6VCQ | CRYSTAL STRUCTURE OF E.COLI RPPH IN COMPLEX WITH GTP | 3.6.1 |
| 6VCR | CRYSTAL STRUCTURE OF E.COLI RPPH IN COMPLEX WITH CTP | 3.6.1 |
| 6VDK | CRYOEM STRUCTURE OF HIV-1 CONSERVED INTASOME CORE | 2.7.7 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 3.1 |
| 6VDL | HCV NS3/4A PROTEASE A156T MUTANT IN COMPLEX WITH GLECAPREVIR | 3.4.22 3.4.21.98 3.6.1.15 3.6.4.13 2.7.7.48 |
| 6VDM | HCV NS3/4A PROTEASE A156T, D168E DOUBLE MUTANT IN COMPLEX WITH GLECAPREVIR | 3.4.22 3.4.21.98 3.6.1.15 3.6.4.13 2.7.7.48 |
| 6VDN | HCV NS3/4A PROTEASE A156T MUTANT | 3.4.22 3.4.21.98 3.6.1.15 3.6.4.13 2.7.7.48 |
| 6VE1 | CRYSTAL STRUCTURE OF ENDO-BETA-N-ACETYLGLUCOSAMINIDASE H AT HIGH PH | 3.2.1.96 |
| 6VFF | DIMER OF HUMAN ADENOSINE DEAMINASE ACTING ON DSRNA (ADAR2) MUTANT E488Q BOUND TO DSRNA SEQUENCE DERIVED FROM HUMAN GLI1 GENE | 3.5.4.37 |
| 6VFY | CRYSTAL STRUCTURE OF MOUSE ACYL-COA THIOESTERASE 7 WITH COA | 3.1.2.2 |
| 6VG5 | DENGUEV-2 CAPSID ST148 INHIBITOR COMPLEX | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 6VGK | CLPP1P2 COMPLEX FROM M. TUBERCULOSIS | 3.4.21.92 |
| 6VGN | CLPP1P2 COMPLEX FROM M. TUBERCULOSIS BOUND TO ADEP | 3.4.21.92 |
| 6VGO | CRYSTAL STRUCTURE OF HUMAN DIPEPTIDASE 3 | 3.4.13.19 |
| 6VGR | CRYSTAL STRUCTURE OF HUMAN DIPEPTIDASE 3 IN COMPLEX WITH FAB OF SC-003 | 3.4.13.19 |
| 6VGY | 2.05 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 6B | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 6VGZ | 2.25 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 6D | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 6VH0 | 1.95 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 6G | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 6VH1 | 2.30 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 6H | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 6VH2 | 2.26 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 7I | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 6VH3 | 2.20 A RESOLUTION STRUCTURE OF MERS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 7J | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 6VH9 | FPHF, STAPHYLOCOCCUS AUREUS FLUOROPHOSPHONATE-BINDING SERINE HYDROLASES F, APO FORM | 3.1.2.12 |
| 6VHD | FPHF, STAPHYLOCOCCUS AUREUS FLUOROPHOSPHONATE-BINDING SERINE HYDROLASES F, KT129 BOUND | 3.1.2.12 |
| 6VHE | FPHF, STAPHYLOCOCCUS AUREUS FLUOROPHOSPHONATE-BINDING SERINE HYDROLASES F, KT130 BOUND | 3.1.2.12 |
| 6VHS | CRYSTAL STRUCTURE OF CTX-M-14 IN COMPLEX WITH BETA-LACTAMASE INHIBITOR ETX1317 | 3.5.2.6 |
| 6VIE | STRUCTURE OF CASPASE-1 IN COMPLEX WITH GASDERMIN D | 3.4.22.36 |
| 6VIN | CRYSTALLOGRAPHIC STRUCTURE OF THE CIRCULARLY PERMUTED HUMAN TASPASE1 PROTEIN | 3.4.25 |
| 6VJ7 | CRYSTAL STRUCTURE OF RED KIDNEY BEAN PURPLE ACID PHOSPHATASE IN COMPLEX WITH ADENOSINE 5'-(BETA,GAMMA IMIDO)TRIPHOSPHATE | 3.1.3.2 |
| 6VJ8 | CRYSTAL STRUCTURE OF GLPG IN COMPLEX WITH PEPTIDE CHLOROMETHYLKETONE INHIBITOR | 3.4.21.105 |
| 6VJ9 | CRYSTAL STRUCTURE OF GLPG IN COMPLEX WITH PEPTIDE BORONATE INHIBITOR | 3.4.21.105 |
| 6VJB | CRYSTAL STRUCTURE OF A CATALYTICALLY INACTIVE CXC CHEMOKINE-DEGRADING PROTEASE SPYCEP FROM STREPTOCOCCUS PYOGENES | 3.4.21.110 |
| 6VJE | CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA PENICILLIN-BINDING PROTEIN 3 (PBP3) COMPLEXED WITH CEFTOBIPROLE | 3.4.16.4 |
| 6VJJ | CRYSTAL STRUCTURE OF WILD-TYPE KRAS4B (GMPPNP-BOUND) IN COMPLEX WITH RAS-BINDING DOMAIN (RBD) OF RAF1/CRAF | 3.6.5.2 |
| 6VJW | CRYSTAL STRUCTURE OF WT HMBD4 COMPLEXED WITH T:G MISMATCH DNA | 3.2.2 |
| 6VKJ | CRYSTAL STRUCTURE OF THE G DOMAIN OF HUMAN GUANYLATE-BINDING PROTEIN 2 (HGBP2) IN COMPLEX WITH GDP | 3.6.5 |
| 6VLM | CORE CATALYTIC DOMAIN OF HIV INTEGRASE IN COMPLEX WITH VIRTUAL SCREENING HIT | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6VLU | FACTOR XIA IN COMPLEX WITH COMPOUND 7 | 3.4.21.27 |
| 6VLV | FACTOR XIA IN COMPLEX WITH COMPOUND 11 | 3.4.21.27 |
| 6VN3 | USP7 IN COMPLEX WITH LIGAND COMPOUND 23 | 3.4.19.12 |
| 6VN4 | USP7 IN COMPLEX WITH LIGAND COMPOUND 1 | 3.4.19.12 |
| 6VN5 | USP7 IN COMPLEX WITH LIGAND COMPOUND 7 | 3.4.19.12 |
| 6VN6 | USP7 IN COMPLEX WITH LIGAND COMPOUND 14 | 3.4.19.12 |
| 6VNO | CRYO-EM STRUCTURE OF THE C-TERMINAL HALF OF THE PARKINSON'S DISEASE-LINKED PROTEIN LEUCINE RICH REPEAT KINASE 2 (LRRK2) | 2.7.11.1 3.6.5 |
| 6VNQ | CRYSTAL STRUCTURE OF DANIO RERIO HISTONE DEACETYLASE 10 IN COMPLEX WITH BISHYDROXAMIC ACID BASED INHIBITOR | 3.5.1.48 3.5.1.62 |
| 6VNU | X-RAY CRYSTAL STRUCTURE OF RUTHENOCENYL-7-AMINOCEPHALOSPORANIC ACID COVALENT ACYL-ENZYME COMPLEX WITH CTX-M-14 E166A BETA-LACTAMASE | 3.5.2.6 |
| 6VOD | HIV-1 WILD TYPE PROTEASE WITH GRL-052-16A, A TRICYCLIC CYCLOHEXANE FUSED TETRAHYDROFURANOFURAN (CHF-THF) DERIVATIVE AS THE P2 LIGAND | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6VOE | HIV-1 WILD TYPE PROTEASE WITH GRL-019-17A, A TRICYCLIC CYCLOHEXANE FUSED TETRAHYDROFURANOFURAN (CHF-THF) DERIVATIVE AS THE P2 LIGAND AND A AMINOBENZOTHIAZOLE(ABT)-BASED P2'-LIGAND | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6VOT | CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGONISA PBP3 COMPLEXED TO GAMMA-LACTAM YU253434 | 3.4.16.4 |
| 6VOY | CRYO-EM STRUCTURE OF HTLV-1 INSTASOME | 3.4.23 2.7.7.49 2.7.7.7 3.1.26.4 2.7.7 3.1 |
| 6VP6 | CRYO-EM STRUCTURE OF THE C-TERMINAL HALF OF THE PARKINSON'S DISEASE-LINKED PROTEIN LEUCINE RICH REPEAT KINASE 2 (LRRK2) | 2.7.11.1 3.6.5 |
| 6VP7 | CRYO-EM STRUCTURE OF THE C-TERMINAL HALF OF THE PARKINSON'S DISEASE-LINKED PROTEIN LEUCINE RICH REPEAT KINASE 2 (LRRK2) | 2.7.11.1 3.6.5 |
| 6VP8 | CRYO-EM STRUCTURE OF THE C-TERMINAL HALF OF THE PARKINSON'S DISEASE-LINKED PROTEIN LEUCINE RICH REPEAT KINASE 2 (LRRK2) | 2.7.11.1 3.6.5 |
| 6VRB | CRYO-EM STRUCTURE OF ACRVIA1-CAS13(CRRNA) COMPLEX | 3.1 |
| 6VRC | CRYO-EM STRUCTURE OF CAS13(CRRNA) | 3.1 |
| 6VRG | STRUCTURE OF HIV-1 INTEGRASE WITH NATIVE AMINO-TERMINAL SEQUENCE | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6VSO | DENGUEV-2 CAPSID STRUCTURE | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 6VSS | ARGINASE FROM MEDICAGO TRUNCATULA | 3.5.3.1 |
| 6VSX | X-RAY CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF BACILLUS SUBTILIS RNA POLYMERASE BINDING HELICASE HELD | 3.6.4.12 |
| 6VTV | CRYSTAL STRUCTURE OF PUUD GAMMA-GLUTAMYL-GAMMA-AMINOBUTYRATE HYDROLASE FROM E. COLI | 3.5.1.94 |
| 6VUA | X-RAY STRUCTURE OF HUMAN CD38 CATALYTIC DOMAIN WITH 2'-CL-ARANAD+ | 3.2.2.6 2.4.99.20 |
| 6VUQ | CRYSTAL STRUCTURE OF CHIKV NSP3 MACRODOMAIN SOAKED WITH ADP-RIBOSE | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6VVQ | HUMAN START DOMAIN OF ACYL-COENZYME A THIOESTERASE 11 (ACOT11) BOUND TO MYRISTIC ACID | 3.1.2 3.1.2.2 |
| 6VWW | CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2. | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6VXS | CRYSTAL STRUCTURE OF ADP RIBOSE PHOSPHATASE OF NSP3 FROM SARS COV-2 | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6VXY | TRIAZOLE BRIDGED SFTI1 INHIBITOR IN COMPLEX WITH BETA-TRYPSIN | 3.4.21.4 |
| 6VYE | 6-PHOSPHOGLUCONOLACTONASE FROM TRYPANOSOMA CRUZI | 3.1.1.31 |
| 6VZG | CRYO-EM STRUCTURE OF STH1-ARP7-ARP9-RTT102 | 3.6.4.12 |
| 6W01 | THE 1.9 A CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2 IN THE COMPLEX WITH A CITRATE | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6W02 | CRYSTAL STRUCTURE OF ADP RIBOSE PHOSPHATASE OF NSP3 FROM SARS COV-2 IN THE COMPLEX WITH ADP RIBOSE | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6W04 | CRYSTAL STRUCTURE OF HAD HYDROLASE, FAMILY IA, VARIANT 3 FROM ENTAMOEBA HISTOLYTICA HM-1:IMSS | 3 |
| 6W0M | HUMAN 8-OXOGUANINE GLYCOSYLASE CROSSLINKED WITH OXOG LESION CONTAINING DNA | 3.2.2 4.2.99.18 |
| 6W0Q | APE1 ENDONUCLEASE PRODUCT COMPLEX D148E | 3.1 4.2.99.18 |
| 6W0R | HUMAN 8-OXOGUANINE GLYCOSYLASE INTERROGATING FULLY INTRAHELICAL UNDAMAGED DNA | 3.2.2 4.2.99.18 |
| 6W0T | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 3.1.3.84 2.1.1 2.7.7 3.1.3.33 3.4.22 3.6.1.15 3.6.4.13 2.7.7.19 2.7.7.48 |
| 6W13 | HUMAN 8-OXOGUANINE GLYCOSYLASE INTERROGATING FULLY INTRAHELICAL OXOG LESION DNA | 3.2.2 4.2.99.18 |
| 6W2A | 1.65 A RESOLUTION STRUCTURE OF SARS-COV 3CL PROTEASE IN COMPLEX WITH INHIBITOR 7J | 3.4.19.12 3.4.22 3.4.22.69 |
| 6W2P | APE1 ENDONUCLEASE PRODUCT COMPLEX L104R | 3.1 4.2.99.18 |
| 6W2Z | CRYSTAL STRUCTURE OF THE BETA LACTAMASE CLASS A PENP FROM BACILLUS SUBTILIS IN THE COMPLEX WITH THE NON-BETA- LACTAM BETA-LACTAMASE INHIBITOR AVIBACTAM | 3.5.2.6 |
| 6W33 | CRYSTAL STRUCTURE OF CLASS A BETA-LACTAMASE FROM BACILLUS CEREUS IN THE COMPLEX WITH THE BETA-LACTAMASE INHIBITOR CLAVULANATE | 3.5.2.6 |
| 6W34 | CRYSTAL STRUCTURE OF CLASS A BETA-LACTAMASE FROM BACILLUS CEREUS | 3.5.2.6 |
| 6W39 | STRUCTURE OF UNPHOSPHORYLATED IRE1 IN COMPLEX WITH G-1749 | 2.7.11.1 3.1.26 |
| 6W3A | STRUCTURE OF UNPHOSPHORYLATED IRE1 IN COMPLEX WITH G-7658 | 2.7.11.1 3.1.26 |
| 6W3B | STRUCTURE OF APO UNPHOSPHORYLATED IRE1 | 2.7.11.1 3.1.26 |
| 6W3C | STRUCTURE OF PHOSPHORYLATED APO IRE1 | 2.7.11.1 3.1.26 |
| 6W3E | STRUCTURE OF PHOSPHORYLATED IRE1 IN COMPLEX WITH G-0701 | 2.7.11.1 3.1.26 |
| 6W3K | STRUCTURE OF UNPHOSPHORYLATED HUMAN IRE1 BOUND TO G-9807 | 2.7.11.1 3.1.26 |
| 6W3L | APE1 EXONUCLEASE SUBSTRATE COMPLEX WILD-TYPE | 3.1 4.2.99.18 |
| 6W3N | APE1 EXONUCLEASE SUBSTRATE COMPLEX D148E | 3.1 4.2.99.18 |
| 6W3Q | APE1 EXONUCLEASE SUBSTRATE COMPLEX L104R | 3.1 4.2.99.18 |
| 6W3U | APE1 EXONUCLEASE SUBSTRATE COMPLEX R237C | 3.1 4.2.99.18 |
| 6W43 | APE1 AP-ENDONUCLEASE PRODUCT COMPLEX R237C | 3.1 4.2.99.18 |
| 6W4B | THE CRYSTAL STRUCTURE OF NSP9 RNA BINDING PROTEIN OF SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6W4I | APE1 Y269A PRODUCT COMPLEX WITH ABASIC DNA | 3.1 4.2.99.18 |
| 6W4T | APE1 Y269A PHOSPHOROTHIOATE SUBSTRATE COMPLEX WITH ABASIC DNA | 3.1 4.2.99.18 |
| 6W50 | FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-OXO-3,6-DIHYDRO- 1(2H)-PYRIDINYL)-10-METHYL-9-OXO-8,16- DIAZATRICYCLO[13.3.1.0~2,7~]NONADECA-1(19),2,4,6,15,17- HEXAEN-5-YL)CARBAMATE | 3.4.21.27 |
| 6W5E | CLASS D BETA-LACTAMASE BSU-2 | 3.5.2.6 |
| 6W5G | CLASS D BETA-LACTAMASE BAT-2 | 3.5.2.6 |
| 6W5J | 1.85 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 7D | 3.4.22.66 3.6.1.15 2.7.7.48 |
| 6W5K | 1.95 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 5G | 3.6.1.15 3.4.22.66 2.7.7.48 |
| 6W5L | 2.1 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH INHIBITOR 7G | 3.6.1.15 3.4.22.66 2.7.7.48 |
| 6W5O | CLASS D BETA-LACTAMASE BAT-2 DELTA MUTANT | 3.5.2.6 |
| 6W61 | CRYSTAL STRUCTURE OF THE METHYLTRANSFERASE-STIMULATORY FACTOR COMPLEX OF NSP16 AND NSP10 FROM SARS COV-2. | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6W63 | STRUCTURE OF COVID-19 MAIN PROTEASE BOUND TO POTENT BROAD-SPECTRUM NON-COVALENT INHIBITOR X77 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6W6Y | CRYSTAL STRUCTURE OF ADP RIBOSE PHOSPHATASE OF NSP3 FROM SARS COV-2 IN COMPLEX WITH AMP | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6W75 | 1.95 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF NSP10 - NSP16 COMPLEX FROM SARS-COV-2 | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6W79 | STRUCTURE OF SARS-COV MAIN PROTEASE BOUND TO POTENT BROAD-SPECTRUM NON-COVALENT INHIBITOR X77 | 3.4.19.12 3.4.22.69 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 2.1.1 3.1.13 3.1 |
| 6W7H | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W7P | CRYSTAL STRUCTURE ANALYSIS OF SPACE-GROWN LYSOZYME - GROUND EXPERIMENT | 3.2.1.17 |
| 6W8E | CRYSTAL STRUCTURE ANALYSIS OF SPACE-GROWN LYSOZYME | 3.2.1.17 |
| 6W8K | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W8M | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W8Q | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W8R | CRYSTAL STRUCTURE OF METACASPASE 4 C139A FROM ARABIDOPSIS | 3.4.22 |
| 6W8S | CRYSTAL STRUCTURE OF METACASPASE 4 FROM ARABIDOPSIS | 3.4.22 |
| 6W8T | CRYSTAL STRUCTURE OF METACASPASE 4 FROM ARABIDOPSIS (MICROCRYSTALS TREATED WITH CALCIUM) | 3.4.22 |
| 6W8Y | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W8Z | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W91 | CO-CRYSTAL STRUCTURES OF CHIKV NSP3 MACRODOMAIN WITH PYRIMIDONE FRAGMENTS | 2.7.7.19 3.1.3.33 3.1.3.84 3.6.1.15 3.6.4.13 |
| 6W9C | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6W9Q | PEPTIDE-BOUND SARS-COV-2 NSP9 RNA-REPLICASE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6W9T | CRYSTAL STRUCTURE OF NEISSERIA MENINGITIDIS CLPP PROTEASE COMPLEX WITH SMALL MOLECULE ACTIVATOR ACP1-06 | 3.4.21.92 |
| 6WA8 | CRYSTAL STRUCTURE OF THE E. COLI TRANSCRIPTION TERMINATION FACTOR RHO | 3.6.4 |
| 6WAZ | +1 EXTENDED HIV-1 REVERSE TRANSCRIPTASE INITIATION COMPLEX CORE (PRE-TRANSLOCATION STATE) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WB0 | +3 EXTENDED HIV-1 REVERSE TRANSCRIPTASE INITIATION COMPLEX CORE (PRE-TRANSLOCATION STATE) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WB1 | +3 EXTENDED HIV-1 REVERSE TRANSCRIPTASE INITIATION COMPLEX CORE (INTERMEDIATE STATE) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WB2 | +3 EXTENDED HIV-1 REVERSE TRANSCRIPTASE INITIATION COMPLEX CORE (DISPLACED STATE) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WBQ | CRYSTAL STRUCTURE OF DANIO RERIO HISTONE DEACETYLASE 10 IN COMPLEX WITH TUBASTATIN A | 3.5.1.48 3.5.1.62 |
| 6WBW | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ETHYL KETONE INHIBITOR | 3.5.1.98 |
| 6WBZ | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ETHYL KETONE INHIBITOR CONTAINING A SPIRO-BICYCLIC GROUP | 3.5.1.98 |
| 6WC1 | PEPTIDE-BOUND SARS-COV-2 NSP9 RNA-REPLICASE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WCD | CRYSTAL STRUCTURE OF XENOPUS LAEVIS APE2 CATALYTIC DOMAIN | 4.2.99.18 3.1 |
| 6WCF | CRYSTAL STRUCTURE OF ADP RIBOSE PHOSPHATASE OF NSP3 FROM SARS-COV-2 IN COMPLEX WITH MES | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WCO | STRUCTURE OF SARS MAIN PROTEASE BOUND TO INHIBITOR X47 | 3.4.19.12 3.4.22.69 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 2.1.1 3.1.13 3.1 |
| 6WCX | FPHF, STAPHYLOCOCCUS AUREUS FLUOROPHOSPHONATE-BINDING SERINE HYDROLASES F, SUBSTRATE BOUND | 3.1.2.12 |
| 6WDV | CRYSTAL STRUCTURE OF DANIO RERIO HISTONE DEACETYLASE 10 IN COMPLEX WITH DIMETHYLAMINOMETHYLINDOLE PHENYLHYDROXAMATE INHIBITOR | 3.5.1.48 3.5.1.62 |
| 6WDW | CRYSTAL STRUCTURE OF DANIO RERIO HISTONE DEACETYLASE 10 IN COMPLEX WITH DIMETHYLAMINOETHYLINDOLE PHENYLHYDROXAMATE INHIBITOR | 3.5.1.48 3.5.1.62 |
| 6WDX | CRYSTAL STRUCTURE OF DANIO RERIO HISTONE DEACETYLASE 10 IN COMPLEX WITH HYDROXYETHYLINDOLE PHENYLHYDROXAMATE INHIBITOR | 3.5.1.48 3.5.1.62 |
| 6WDY | CRYSTAL STRUCTURE OF DANIO RERIO HISTONE DEACETYLASE 10 IN COMPLEX WITH INDOLE PHENYLHYDROXAMATE INHIBITOR | 3.5.1.48 3.5.1.62 |
| 6WE0 | WHEAT DWARF VIRUS REP DOMAIN COMPLEXED WITH A SINGLE-STRANDED DNA 10-MER COMPRISING THE CLEAVAGE SITE | 3.1.21 |
| 6WE1 | WHEAT DWARF VIRUS REP DOMAIN COMPLEXED WITH A SINGLE-STRANDED DNA 8-MER COMPRISING THE CLEAVAGE SITE | 3.1.21 |
| 6WE5 | CRYSTAL STRUCTURE OF AN INORGANIC PYROPHOSPHATASE FROM CHLAMYDIA TRACHOMATIS D/UW-3/CX | 3.6.1.1 |
| 6WEN | CRYSTAL STRUCTURE OF ADP RIBOSE PHOSPHATASE OF NSP3 FROM SARS-COV-2 IN THE APO FORM | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WEQ | DENV1 NS1 IN COMPLEX WITH NEUTRALIZING 2B7 FAB FRAGMENT | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 6WEY | HIGH-RESOLUTION STRUCTURE OF THE SARS-COV-2 NSP3 MACRO X DOMAIN | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WG5 | HUMAN ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 4 (ENTPD4, NTPDASE 4) | 3.6.1.6 |
| 6WGD | CRYSTAL STRUCTURE OF A 6-PHOSPHO-BETA-GLUCOSIDASE FROM BACILLUS LICHENIFORMIS | 3.2.1.86 |
| 6WGF | ATOMIC MODEL OF MUTANT MCM2-7 HEXAMER WITH MCM6 WHD TRUNCATION | 3.6.4.12 |
| 6WGG | ATOMIC MODEL OF PRE-INSERTION MUTANT OCCM-DNA COMPLEX(ORC-CDC6-CDT1-MCM2-7 WITH MCM6 WHD TRUNCATION) | 3.6.4.12 |
| 6WGH | CRYSTAL STRUCTURE OF GDP-BOUND NRAS WITH TEN RESIDUES LONG INTERNAL TANDEM DUPLICATION IN THE SWITCH II REGION | 3.6.5.2 |
| 6WGN | CRYSTAL STRUCTURE OF K-RAS(G12D) GPPNHP BOUND TO CYCLIC PEPTIDE LIGAND KD2 | 3.6.5.2 |
| 6WGP | THE CRYSTAL STRUCTURE OF A BETA LACTAMASE FROM XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS STR. ATCC 33913 | 3.5.2.6 |
| 6WGQ | THE CRYSTAL STRUCTURE OF A BETA-LACTAMASE FROM SHIGELLA FLEXNERI 2A STR. 2457T | 3.5.2.6 |
| 6WGR | THE CRYSTAL STRUCTURE OF A BETA-LACTAMASE FROM STAPHYLOCOCCUS AUREUS SUBSP. AUREUS USA300_TCH1516 | 3.5.2.6 |
| 6WHF | CLASS C BETA-LACTAMASE FROM ESCHERICHIA COLI IN COMPLEX WITH CEPHALOTHIN | 3.5.2.6 |
| 6WHL | THE CRYSTAL STRUCTURE OF A BETA-LACTAMASE FROM LEGIONELLA PNEUMOPHILA STR. PARIS | 3.5.2.6 |
| 6WIF | CLASS C BETA-LACTAMASE FROM ACINETOBACTER BAUMANNII IN COMPLEX WITH 4-(ETHYL(METHYL)CARBAMOYL)PHENYL BORONIC ACID | 3.5.2.6 |
| 6WII | CRYSTAL STRUCTURE OF THE K. PNEUMONIAE LPXH/JH-LPH-41 COMPLEX | 3.6.1.54 |
| 6WIP | CLASS A BETA-LACTAMASE FROM MICROMONOSPORA AURANTIACA ATCC 27029 | 3.5.2.6 |
| 6WIQ | CRYSTAL STRUCTURE OF THE CO-FACTOR COMPLEX OF NSP7 AND THE C-TERMINAL DOMAIN OF NSP8 FROM SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WJC | MUSCARINIC ACETYLCHOLINE RECEPTOR 1 - MUSCARINIC TOXIN 7 COMPLEX | 3.2.1.17 |
| 6WJM | THE CRYSTAL STRUCTURE BETA-LACTAMASE FROM DESULFARCULUS BAARSII DSM 2075 | 3.5.2.6 |
| 6WJT | 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF NSP16-NSP10 HETERODIMER FROM SARS-COV-2 IN COMPLEX WITH S-ADENOSYL-L-HOMOCYSTEINE | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6WKQ | 1.98 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF NSP16-NSP10 HETERODIMER FROM SARS-COV-2 IN COMPLEX WITH SINEFUNGIN | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6WLC | CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2 IN THE COMPLEX WITH URIDINE-5'-MONOPHOSPHATE | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6WNL | HUMAN ARTEMIS/SNM1C CATALYTIC DOMAIN, CRYSTAL FORM 2 | 3.1 |
| 6WNP | X-RAY STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO BOCEPREVIR AT 1.45 A | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WNY | CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH (Z)-FLUORO-OLEFIN CONTAINING COMPOUND 15 | 3.4.23.46 |
| 6WO0 | HUMAN ARTEMIS/SNM1C CATALYTIC DOMAIN, CRYSTAL FORM 1 | 3.1 |
| 6WO3 | STRUCTURE OF HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 CORE FROM GENOTYPE 6A BOUND TO BROADLY NEUTRALIZING ANTIBODY U1 | 2.7.7.48 3.4.21.98 3.6.1.15 3.6.4.13 |
| 6WO4 | STRUCTURE OF HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E2 CORE FROM GENOTYPE 6A BOUND TO BROADLY NEUTRALIZING ANTIBODY HC11 | 2.7.7.48 3.4.21.98 3.6.1.15 3.6.4.13 |
| 6WOJ | STRUCTURE OF THE SARS-COV-2 MACRODOMAIN (NSP3) IN COMPLEX WITH ADP-RIBOSE | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WPF | STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH DSDNA AND D4T | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WPH | STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH DSDNA AND (-)-FTC | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WPJ | STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH DSDNA AND D4T | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6WPK | SARM1 AUTOINHIBITED CONFORMATION | 3.2.2.6 3.2.2 |
| 6WQ3 | CRYSTAL STRUCTURE OF NSP16-NSP10 HETERODIMER FROM SARS-COV-2 IN COMPLEX WITH 7-METHYL-GPPPA AND S-ADENOSYL-L-HOMOCYSTEINE. | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6WQD | THE 1.95 A CRYSTAL STRUCTURE OF THE CO-FACTOR COMPLEX OF NSP7 AND THE C-TERMINAL DOMAIN OF NSP8 FROM SARS-COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WQF | STRUCTURAL PLASTICITY OF THE SARS-COV-2 3CL MPRO ACTIVE SITE CAVITY REVEALED BY ROOM TEMPERATURE X-RAY CRYSTALLOGRAPHY | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WQY | GH5-4 BROAD SPECIFICITY ENDOGLUCANASE FROM BACTEROIDES SALANITRONIS | 3.2.1.4 |
| 6WRE | CRYSTAL STRUCTURE OF MOUSE DXO IN COMPLEX WITH 5'-OH RNA SUBSTRATE MIMIC AND CALCIUM ION | 3.1.13 3.6.1 |
| 6WRH | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 , C111S MUTANT | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WRL | THE INTERACTION OF CHLORIDO(1,5-CYCLOOCTADIENE)([4-(2-((TERT-BUTOXYCARBONYL)AMINO)-3-METHOXY-3-OXOPROPYL)-1,3-DIMETHYL-1H-IMIDAZOL-3-IDE])RHODIUM(I) WITH HEWL AFTER 1 WEEK | 3.2.1.17 |
| 6WRM | THE INTERACTION OF CHLORIDO(1,5-CYCLOOCTADIENE)([4-(2-((TERT-BUTOXYCARBONYL)AMINO)-3-METHOXY-3-OXOPROPYL)-1,3-DIMETHYL-1H-IMIDAZOL-3-IDE])RHODIUM(I) WITH HEWL AFTER 1 MONTH | 3.2.1.17 |
| 6WRO | CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM BUT NO LITHIUM AT 3 ANGSTROM RESOLUTION | 3.1.3.57 |
| 6WRR | CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM AND LITHIUM AT 2.5 ANGSTROM RESOLUTION | 3.1.3.57 |
| 6WRY | CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM AFTER ADDITION OF INOSITOL 1,3,4-TRISPHOSPHATE AT 2.5 ANGSTROM RESOLUTION | 3.1.3.57 |
| 6WRZ | CRYSTAL STRUCTURE OF NSP16-NSP10 HETERODIMER FROM SARS-COV-2 WITH 7-METHYL-GPPPA AND S-ADENOSYL-L-HOMOCYSTEINE IN THE ACTIVE SITE AND SULFATES IN THE MRNA BINDING GROOVE. | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6WTC | CRYSTAL STRUCTURE OF THE SECOND FORM OF THE CO-FACTOR COMPLEX OF NSP7 AND THE C-TERMINAL DOMAIN OF NSP8 FROM SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WTJ | FELINE CORONAVIRUS DRUG INHIBITS THE MAIN PROTEASE OF SARS-COV-2 AND BLOCKS VIRUS REPLICATION | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WTK | FELINE CORONAVIRUS DRUG INHIBITS THE MAIN PROTEASE OF SARS-COV-2 AND BLOCKS VIRUS REPLICATION | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WTM | FELINE CORONAVIRUS DRUG INHIBITS THE MAIN PROTEASE OF SARS-COV-2 AND BLOCKS VIRUS REPLICATION | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WTT | CRYSTALS STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE WITH INHIBITOR GC-376 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WUF | CRYSTAL STRUCTURE OF MOUSE DXO IN COMPLEX WITH 3'-FADP | 3.1.13 3.6.1 |
| 6WUG | CRYSTAL STRUCTURE OF S. POMBE RAI1 IN COMPLEX WITH 3'-FADP | 3.6.1 |
| 6WUI | CRYSTAL STRUCTURE OF MUTANT S. POMBE RAI1 (E150S/E199Q/E239Q) IN COMPLEX WITH 3'-FADP | 3.6.1 |
| 6WUK | CRYSTAL STRUCTURE OF MOUSE DXO IN COMPLEX WITH COA | 3.1.13 3.6.1 |
| 6WUR | CRYSTAL STRUCTURE OF PRL-2 PHOSPHATASE C101D MUTANT IN COMPLEX WITH THE BATEMAN DOMAIN OF CNNM3 MAGNESIUM TRANSPORTER | 3.1.3.48 |
| 6WUU | CRYSTAL STRUCTURE OF THE SARS COV-2 PAPAIN-LIKE PROTEASE IN COMPLEX WITH PEPTIDE INHIBITOR VIR250 | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WVN | CRYSTAL STRUCTURE OF NSP16-NSP10 FROM SARS-COV-2 IN COMPLEX WITH 7-METHYL-GPPPA AND S-ADENOSYLMETHIONINE. | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6WWD | CRYSTAL STRUCTURE OF NUCLEOSIDE-TRIPHOSPHATASE / DITP/XTP PYROPHOSPHATASE FROM MYCOBACTERIUM ABSCESSUS ATCC 19977 / DSM 44196 | 3.6.1.66 |
| 6WX4 | CRYSTAL STRUCTURE OF THE SARS COV-2 PAPAIN-LIKE PROTEASE IN COMPLEX WITH PEPTIDE INHIBITOR VIR251 | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WXC | CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2 IN THE COMPLEX WITH POTENTIAL REPURPOSING DRUG TIPIRACIL | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6WXD | SARS-COV-2 NSP9 RNA-REPLICASE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6WY4 | CRYSTAL STRUCTURE OF WILD TYPE CLASS D BETA-LACTAMASE FROM CLOSTRIDIUM DIFFICILE 630 | 3.5.2.6 |
| 6WYW | CRYSTAL STRUCTURE OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE IN COMPLEX WITH L-ASP AT PH 4.5 | 3.5.1.38 |
| 6WYX | CRYSTAL STRUCTURE OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE IN COMPLEX WITH L-ASP AT PH 5.0 | 3.5.1.38 |
| 6WYY | CRYSTAL STRUCTURE OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE IN COMPLEX WITH L-GLU AT PH 6.5 | 3.5.1.38 |
| 6WYZ | CRYSTAL STRUCTURE OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE (MUTANT K173M) IN COMPLEX WITH D-GLU AT PH 5.5 | 3.5.1.38 |
| 6WZ4 | COMPLEX OF MUTANT (K173M) OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE WITH L-ASP AT PH 6. COVALENT ACYL-ENZYME INTERMEDIATE | 3.5.1.38 |
| 6WZ6 | COMPLEX OF MUTANT (K173M) OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE WITH L-GLU AT PH 5. COVALENT ACYL-ENZYME INTERMEDIATE | 3.5.1.38 |
| 6WZ8 | COMPLEX OF PSEUDOMONAS 7A GLUTAMINASE-ASPARAGINASE WITH CITRATE ANION AT PH 5.5. COVALENT ACYL-ENZYME INTERMEDIATE | 3.5.1.38 |
| 6WZU | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 , P3221 SPACE GROUP | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6X1B | CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2 IN THE COMPLEX WITH THE PRODUCT NUCLEOTIDE GPU. | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6X1Q | 1.8 ANGSTROM RESOLUTION STRUCTURE OF B-GALACTOSIDASE WITH A 200 KV CRYOARM ELECTRON MICROSCOPE | 3.2.1.23 |
| 6X25 | CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE INPP1 IN COMPLEX GADOLINIUM AFTER ADDITION OF INOSITOL 1,3,4-TRISPHOSPHATE AND LITHIUM AT 3.2 ANGSTROM RESOLUTION | 3.1.3.57 |
| 6X2D | CRYSTAL STRUCTURE OF DNASE I DOMAIN OF RIBONUCLEASE E FROM VIBRIO CHOLERAE | 3.1.26.12 |
| 6X42 | HIGH RESOLUTION CRYSTAL STRUCTURE ANALYSIS OF SERA5E FROM PLASMODIUM FALCIPARUM | 3.4.22 |
| 6X44 | HIGH RESOLUTION CRYSTAL STRUCTURE ANALYSIS OF SERA5 PROENZYME FROM PLASMODIUM FALCIPARUM | 3.4.22 |
| 6X47 | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-2-NAPHTHONITRILE (JLJ649), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X49 | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH 7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-2-NAPHTHONITRILE (JLJ649), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4A | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH 5-CHLORO-7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-8-METHYL-2-NAPHTHONITRILE (JLJ651), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4B | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-5-FLUORO-8-METHYL-2-NAPHTHONITRILE (JLJ655), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4C | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)-4-FLUOROPHENOXY)-5,8-DIMETHYL-2-NAPHTHONITRILE (JLJ658), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4D | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 5-(CYCLOPROPYLMETHYL)-7-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-8-METHYL-2-NAPHTHONITRILE (JLJ678), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4E | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH METHYL 2-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)ACETATE (JLJ681), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4F | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (Y181C) VARIANT IN COMPLEX WITH METHYL 2-(6-CYANO-3-(2-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENOXY)-4-METHYLNAPHTHALEN-1-YL)ACETATE (JLJ681), A NON-NUCLEOSIDE INHIBITOR | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 6X4I | CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2 IN THE COMPLEX WITH 3'-URIDINEMONOPHOSPHATE | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6X5J | DISCOVERY OF HYDROXY PYRIMIDINE FACTOR IXA INHIBITORS | 3.4.21.22 |
| 6X5L | DISCOVERY OF HYDROXY PYRIMIDINE FACTOR IXA INHIBITORS | 3.4.21.22 |
| 6X5P | DISCOVERY OF HYDROXY PYRIMIDINE FACTOR IXA INHIBITORS | 3.4.21.22 |
| 6X60 | CLPP2 FROM CHLAMYDIA TRACHOMATIS WITH RESOLVED HANDLE LOOP | 3.4.21.92 |
| 6X7U | CRYSTAL STRUCTURE OF THE HUMAN NUDIX HYDROLASE NUDT16 IN COMPLEX WITH FAD | 3.6.1.62 3.6.1.64 |
| 6X7V | CRYSTAL STRUCTURE OF THE HUMAN NUDIX HYDROLASE NUDT16 | 3.6.1.62 3.6.1.64 |
| 6X88 | PDE6 CHICKEN GAF DOMAIN | 3.1.4.35 |
| 6X9Y | THE CRYSTAL STRUCTURE OF A BETA-LACTAMASE FROM ESCHERICHIA COLI CFT073 | 3.5.2.6 |
| 6XA4 | CRYSTAL STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE IN COMPLEX WITH UAW241 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XA9 | SARS COV-2 PLPRO IN COMPLEX WITH ISG15 C-TERMINAL DOMAIN PROPARGYLAMIDE | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XAA | SARS COV-2 PLPRO IN COMPLEX WITH UBIQUITIN PROPARGYLAMIDE | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XAS | CRYOEM STRUCTURE OF E. COLI RHO-DEPENDENT TRANSCRIPTION PRE-TERMINATION COMPLEX | 3.6.4 |
| 6XAV | CRYOEM STRUCTURE OF E. COLI RHO-DEPENDENT TRANSCRIPTION PRE-TERMINATION COMPLEX BOUND WITH NUSG | 3.6.4 |
| 6XB0 | ROOM TEMPERATURE X-RAY CRYSTALLOGRAPHY REVEALS CATALYTIC CYSTEINE IN THE SARS-COV-2 3CL MPRO IS HIGHLY REACTIVE: INSIGHTS FOR ENZYME MECHANISM AND DRUG DESIGN | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XB1 | ROOM TEMPERATURE X-RAY CRYSTALLOGRAPHY REVEALS CATALYTIC CYSTEINE IN THE SARS-COV-2 3CL MPRO IS HIGHLY REACTIVE: INSIGHTS FOR ENZYME MECHANISM AND DRUG DESIGN | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XB2 | ROOM TEMPERATURE X-RAY CRYSTALLOGRAPHY REVEALS CATALYTIC CYSTEINE IN THE SARS-COV-2 3CL MPRO IS HIGHLY REACTIVE: INSIGHTS FOR ENZYME MECHANISM AND DRUG DESIGN | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XB8 | ADENO-ASSOCIATED VIRUS ORIGIN BINDING DOMAIN IN COMPLEX WITH SSDNA | 3.6.4.12 |
| 6XBG | CRYSTAL STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE IN COMPLEX WITH INHIBITOR UAW246 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XBH | CRYSTAL STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE IN COMPLEX WITH INHIBITOR UAW247 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XBI | CRYSTAL STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE IN COMPLEX WITH INHIBITOR UAW248 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XC0 | CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 SPACKLE AND LYSOZYME IN MONOCLINIC FORM | 3.2.1.17 |
| 6XC1 | CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 SPACKLE AND LYSOZYME IN ORTHORHOMBIC FORM | 3.2.1.17 |
| 6XCB | STRUCTURE OF THE C. BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN PROTEASE IN COMPLEX WITH COVALENT INHIBITOR 20 | 3.4.24.69 |
| 6XCC | STRUCTURE OF THE C. BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN PROTEASE IN COMPLEX WITH COVALENT INHIBITOR 21 | 3.4.24.69 |
| 6XCE | STRUCTURE OF THE C. BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN PROTEASE IN COMPLEX WITH COVALENT INHIBITOR 53 | 3.4.24.69 |
| 6XCF | STRUCTURE OF THE C. BOTULINUM NEUROTOXIN SEROTYPE A LIGHT CHAIN PROTEASE IN COMPLEX WITH NONCOVALENT INHIBITOR 59 | 3.4.24.69 |
| 6XCH | ROOM-TEMPERATURE X-RAY CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH LEUPEPTIN | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XD0 | DENGUE SEROTYPE 3 RNA-DEPENDENT RNA POLYMERASE BOUND TO NITD-434 | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 6XD1 | DENGUE SEROTYPE 3 RNA-DEPENDENT RNA POLYMERASE BOUND TO NITD-640 | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 6XD5 | APO KPC-2 N170A MUTANT AT 1.20 A | 3.5.2.6 |
| 6XD7 | KPC-2 N170A MUTANT BOUND TO HYDROLYZED AMPICILLIN AT 1.65 A | 3.5.2.6 |
| 6XDH | CRYSTAL STRUCTURE OF NENDOU (URIDYLATE-SPECIFIC ENDORIBONUCLEASE, NSP15) FROM BETACORONAVIRUS SARS-COV-2 | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 6XDM | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH AN ARYL KETONE INHIBITOR | 3.5.1.98 |
| 6XEB | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND E) | 3.5.1.98 |
| 6XEC | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH KETONE INHIBITOR (COMPOUND O) | 3.5.1.98 |
| 6XEO | STRUCTURE OF MFD BOUND TO DSDNA | 3.6.4 |
| 6XEZ | STRUCTURE OF SARS-COV-2 REPLICATION-TRANSCRIPTION COMPLEX BOUND TO NSP13 HELICASE - NSP13(2)-RTC | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XF7 | SLP | 3.6.4.13 |
| 6XFN | CRYSTAL STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE IN COMPLEX WITH UAW243 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XFS | CLASS C BETA-LACTAMASE FROM ESCHERICHIA COLI IN COMPLEX WITH TAZOBACTAM | 3.5.2.6 |
| 6XG1 | CLASS C BETA-LACTAMASE FROM ESCHERICHIA COLI | 3.5.2.6 |
| 6XG3 | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 , C111S MUTANT, AT ROOM TEMPERATURE | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XGU | CRYSTAL STRUCTURE OF KRAS-Q61R (GMPPNP-BOUND) IN COMPLEX WITH RAS-BINDING DOMAIN (RBD) AND CYSTEINE-RICH DOMAIN (CRD) OF RAF1/CRAF | 3.6.5.2 |
| 6XGV | CRYSTAL STRUCTURE OF KRAS-G13D (GMPPNP-BOUND) IN COMPLEX WITH RAS-BINDING DOMAIN (RBD) AND CYSTEINE-RICH DOMAIN (CRD) OF RAF1/CRAF | 3.6.5.2 |
| 6XHA | CRYSTAL STRUCTURE OF KRAS-G12V (GMPPNP-BOUND) IN COMPLEX WITH RAS-BINDING DOMAIN (RBD) AND CYSTEINE-RICH DOMAIN (CRD) OF RAF1/CRAF | 3.6.5.2 |
| 6XHB | CRYSTAL STRUCTURE OF WILD-TYPE KRAS (GMPPNP-BOUND) IN COMPLEX WITH RAS-BINDING DOMAIN (RBD) AND CYSTEINE-RICH DOMAIN (CRD) OF RAF1/CRAF (CRYSTAL FORM II) | 3.6.5.2 |
| 6XHL | COVALENT COMPLEX OF SARS-COV MAIN PROTEASE WITH N-[(2S)-1-({(2S,3S)-3,4-DIHYDROXY-1-[(3S)-2-OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)-4-METHYL-1-OXOPENTAN-2-YL]-4-METHOXY-1H-INDOLE-2-CARBOXAMIDE | 3.4.22.69 3.4.19.12 3.4.22 |
| 6XHM | COVALENT COMPLEX OF SARS-COV-2 MAIN PROTEASE WITH N-[(2S)-1-({(2S,3S)-3,4-DIHYDROXY-1-[(3S)-2-OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)-4-METHYL-1-OXOPENTAN-2-YL]-4-METHOXY-1H-INDOLE-2-CARBOXAMIDE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XHN | COVALENT COMPLEX OF SARS-COV MAIN PROTEASE WITH 4-METHOXY-N-[(2S)-4-METHYL-1-OXO-1-({(2S)-3-OXO-1-[(3S)-2-OXOPYRROLIDIN-3-YL]BUTAN-2-YL}AMINO)PENTAN-2-YL]-1H-INDOLE-2-CARBOXAMIDE | 3.4.22.69 3.4.19.12 3.4.22 |
| 6XHO | COVALENT COMPLEX OF SARS-COV MAIN PROTEASE WITH ETHYL (4R)-4-({N-[(4-METHOXY-1H-INDOL-2-YL)CARBONYL]-L-LEUCYL}AMINO)-5-[(3S)-2-OXOPYRROLIDIN-3-YL]PENTANOATE | 3.4.22.69 3.4.19.12 3.4.22 |
| 6XHU | ROOM TEMPERATURE X-RAY CRYSTALLOGRAPHY REVEALS OXIDATION AND REACTIVITY OF CYSTEINE RESIDUES IN SARS-COV-2 3CL MPRO: INSIGHTS FOR ENZYME MECHANISM AND DRUG DESIGN | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XI7 | CRYSTAL STRUCTURE OF WILD-TYPE KRAS (GMPPNP-BOUND) IN COMPLEX WITH RAS-BINDING DOMAIN (RBD) AND CYSTEINE-RICH DOMAIN (CRD) OF RAF1/CRAF (CRYSTAL FORM I) | 3.6.5.2 |
| 6XIB | PCSK9(DELTACRD) IN COMPLEX WITH CYCLIC PEPTIDE 30 | 3.4.21 |
| 6XIC | PCSK9(DELTACRD) IN COMPLEX WITH CYCLIC PEPTIDE 40 | 3.4.21 |
| 6XID | PCSK9(DELTACRD) IN COMPLEX WITH CYCLIC PEPTIDE 51 | 3.4.21 |
| 6XIE | PCSK9(DELTACRD) IN COMPLEX WITH CYCLIC PEPTIDE 77 | 3.4.21 |
| 6XIF | PCSK9(DELTACRD) IN COMPLEX WITH CYCLIC PEPTIDE 83 | 3.4.21 |
| 6XIP | THE 1.5 A CRYSTAL STRUCTURE OF THE CO-FACTOR COMPLEX OF NSP7 AND THE C-TERMINAL DOMAIN OF NSP8 FROM SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XJ3 | CRYSTAL STRUCTURE OF CLASS D BETA-LACTAMASE FROM KLEBSIELLA QUASIPNEUMONIAE IN COMPLEX WITH AVIBACTAM | 3.5.2.6 |
| 6XJ8 | KPC-2 N170A MUTANT BOUND TO HYDROLYZED IMIPENEM AT 2.05 A | 3.5.2.6 |
| 6XJB | IGA1 PROTEASE | 3.4.24.13 |
| 6XKF | THE CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH OXIDIZED CYS145 (SULFENIC ACID CYSTEINE). | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XKH | THE 1.28A CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH OXIDIZED C145 (SULFINIC ACID CYSTEINE) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XKI | CRYSTAL STRUCTURE OF EIF4A-I IN COMPLEX WITH RNA BOUND TO DES-MEPATEA, A PATEAMINE A ANALOG | 3.6.4.13 |
| 6XKM | ROOM TEMPERATURE STRUCTURE OF SARS-COV-2 NSP10/NSP16 METHYLTRANSFERASE IN A COMPLEX WITH SAM DETERMINED BY FIXED-TARGET SERIAL CRYSTALLOGRAPHY | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 6XMJ | HUMAN 20S PROTEASOME BOUND TO AN ENGINEERED 11S (PA26) ACTIVATOR | 3.4.25.1 |
| 6XMK | 1.70 A RESOLUTION STRUCTURE OF SARS-COV-2 3CL PROTEASE IN COMPLEX WITH INHIBITOR 7J | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XMR | X-RAY CRYSTALLOGRAPHIC STRUCTURE MODEL OF LACTOCOCCUS LACTIS PROLIDASE MUTANT H38S | 3.4.13.9 |
| 6XNX | STRUCTURE OF RAG1 (R848M/E649V)-RAG2-DNA STRAND TRANSFER COMPLEX (DYNAMIC-FORM) | 3.1 2.3.2.27 |
| 6XNY | STRUCTURE OF RAG1 (R848M/E649V)-RAG2-DNA STRAND TRANSFER COMPLEX (PAIRED-FORM) | 3.1 2.3.2.27 |
| 6XNZ | STRUCTURE OF RAG1 (R848M/E649V)-RAG2-DNA TARGET CAPTURE COMPLEX | 3.1 2.3.2.27 |
| 6XOA | THE CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH C145S MUTATION | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XOB | CRYOEM STRUCTURE OF EASTERN EQUINE ENCEPHALITIS (EEEV) VLP WITH FAB EEEV-143. | 3.4.21.90 |
| 6XOK | X-RAY STRUCTURE OF THE RHOMBOHEDRAL FORM OF THE LIPASE FROM THERMOMYCES LANUGINOSA AT 1.3 A RESOLUTION | 3.1.1.3 |
| 6XPB | STRUCTURE OF HUMAN GGT1 IN COMPLEX WITH 2-AMINO-4-(((1-((CARBOXYMETHYL)AMINO)-1-OXOBUTAN-2-YL)OXY)(PHENOXY)PHOSPHORYL)BUTANOIC ACID (ACPB) MOLECULE | 3.4.19.13 2.3.2.2 3.4.19.14 |
| 6XPC | STRUCTURE OF HUMAN GGT1 IN COMPLEX WITH FULL GSH MOLECULE | 3.4.19.13 2.3.2.2 3.4.19.14 |
| 6XPG | CRYSTAL STRUCTURE OF SIALATE O-ACETYLESTERASE FROM BACTEROIDES VULGATUS BY SERIAL CRYSTALLOGRAPHY | 3 |
| 6XPM | CRYSTAL STRUCTURE OF SIALATE O-ACETYLESTERASE FROM BACTEROIDES VULGATUS WITH MICROFLUIDICS CRYSTALS AT ROOM TEMPERATURE | 3 |
| 6XQB | SARS-COV-2 RDRP/RNA COMPLEX | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XQS | ROOM-TEMPERATURE X-RAY CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH TELAPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XQT | ROOM-TEMPERATURE X-RAY CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH NARLAPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XQU | ROOM-TEMPERATURE X-RAY CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH BOCEPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XR3 | X-RAY STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO GRL-024-20 AT 1.45 A | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6XRK | GH5-4 BROAD SPECIFICITY ENDOGLUCANASE FROM AN UNCULTURED BOVINE RUMEN CILIATE | 3 |
| 6XRO | CRYSTAL STRUCTURE OF GLPG IN COMPLEX WITH PEPTIDE BORONATE INHIBITOR, AC-KRFRSMQYSA-B(OH)2 | 3.4.21.105 |
| 6XRP | CRYSTAL STRUCTURE OF GLPG IN COMPLEX WITH PEPTIDE KETOAMIDE INHIBITOR, AC-RVWHA-KETOAMIDE-PHENYLBUTYL | 3.4.21.105 |
| 6XRV | X-RAY STRUCTURE OF THE MONOCLINIC CRYSTAL FORM AT 1.43 A RESOLUTION OF LIPASE FROM THERMOMYCES (HUMICOLA) LANUGINOSA AT 173 K | 3.1.1.3 |
| 6XS3 | X-RAY STRUCTURE OF THE MONOCLINIC CRYSTAL FORM AT 2.48 A RESOLUTION OF LIPASE FROM THERMOMYCES (HUMICOLA) LANUGINOSA AT 298 K | 3.1.1.3 |
| 6XSB | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS A132S AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSC | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS V23T AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSE | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS F34Y AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSF | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS T41V AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSG | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS V66T AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSH | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS T62V AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSI | CRYSTAL STRUCTURE OF STAPHYLOCOCCAL NUCLEASE VARIANT DELTA+PHS V104T AT CRYOGENIC TEMPERATURE | 3.1.31.1 |
| 6XSJ | X-RAY STRUCTURE OF A MONOCLINIC FORM OF ALPHA AMYLASE FROM ASPERGILLUS AT 1.4 A RESOLUTION | 3.2.1.1 |
| 6XSV | X-RAY STRUCTURE OF A TETRAGONAL CRYSTAL FORM OF ALPHA AMYLASE FROM ASPERGILLUS ORYZAE (TALA-AMYLASE) AT 1.65 A RESOLUTION | 3.2.1.1 |
| 6XT5 | JACK BEAN ASPARAGINYL ENDOPEPTIDASE | 3.4.22.34 |
| 6XT8 | CRYSTAL STRUCTURE OF HALOALKANE DEHALOGENASE VARIANT DHAA115 DOMAIN-SWAPPED DIMER TYPE-2 | 3.8.1.5 |
| 6XTA | RECOMBINANT HUMAN BUTYRYLCHOLINESTERASE IN COMPLEX WITH (2S)-N-[2-(1-BENZYLAZEPAN-4-YL)ETHYL]-2-(BUTYLAMINO)-3-(1H-INDOL-3-YL)PROPANAMIDE | 3.1.1.8 |
| 6XTX | CRYOEM STRUCTURE OF HUMAN CMG BOUND TO ATPGAMMAS AND DNA | 3.6.4.12 |
| 6XTY | CRYOEM STRUCTURE OF HUMAN CMG BOUND TO AND-1 (CMGA) | 3.6.4.12 |
| 6XUE | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH A2396 (COMPOUND 74 IN PUBLICATION) IN THE CLOSED FORM IN CRYSTAL FORM IV | 3.1.3.5 |
| 6XUG | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH A2410 (COMPOUND 53 IN PUBLICATION) IN THE CLOSED FORM IN CRYSTAL FORM IV | 3.1.3.5 |
| 6XUQ | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH A1618 (COMPOUND 1B IN PUBLICATION) IN THE CLOSED STATE IN CRYSTAL FORM III | 3.1.3.5 |
| 6XUX | CRYSTAL STRUCTURE OF MEGABODY MB-NB207-CYGJK_NO | 3.2.1 |
| 6XVP | CRYSTAL STRUCTURE OF NEPRILYSIN IN COMPLEX WITH SAMPATRILAT. | 3.4.24.11 |
| 6XXW | STRUCTURE OF BETA-D-GLUCURONIDASE FOR DICTYOGLOMUS THERMOPHILUM. | 3.2.1.31 |
| 6XY9 | CRYSTAL STRUCTURE OF HALOALKANE DEHALOGENASE DBEA-M1 LOOP VARIANT FROM BRADYRHIZOBIUM ELKANII | 3.8.1.5 |
| 6XYK | CRYSTAL STRUCTURE OF BOVINE TRYPSIN AT ROOM TEMPERATURE. | 3.4.21.4 |
| 6XYR | STRUCTURE OF THE T4LNANO FUSION PROTEIN | 3.2.1.17 |
| 6XYS | UPDATE OF NATIVE ACETYLCHOLINESTERASE FROM DROSOPHILA MELANOGASTER | 3.1.1.7 |
| 6XYU | UPDATE OF ACHE FROM DROSOPHILA MELANOGASTER COMPLEX WITH TACRINE DERIVATIVE 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE | 3.1.1.7 |
| 6XYY | UPDATE OF ACHE FROM DROSOPHILA MELANOGASTER COMPLEX WITH TACRINE DERIVATIVE 9-(3-PHENYLMETHYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE | 3.1.1.7 |
| 6XZQ | INFLUENZA C VIRUS POLYMERASE IN COMPLEX WITH HUMAN ANP32A - SUBCLASS 1 | 3.1 |
| 6Y0H | HIGH RESOLUTION STRUCTURE OF GH11 XYLANASE FROM NECTRIA HAEMATOCOCCA | 3.2.1.8 |
| 6Y2E | CRYSTAL STRUCTURE OF THE FREE ENZYME OF THE SARS-COV-2 (2019-NCOV) MAIN PROTEASE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Y2F | CRYSTAL STRUCTURE (MONOCLINIC FORM) OF THE COMPLEX RESULTING FROM THE REACTION BETWEEN SARS-COV-2 (2019-NCOV) MAIN PROTEASE AND TERT-BUTYL (1-((S)-1-(((S)-4-(BENZYLAMINO)-3,4-DIOXO-1-((S)-2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)AMINO)-3-CYCLOPROPYL-1-OXOPROPAN-2-YL)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)CARBAMATE (ALPHA-KETOAMIDE 13B) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Y2G | CRYSTAL STRUCTURE (ORTHORHOMBIC FORM) OF THE COMPLEX RESULTING FROM THE REACTION BETWEEN SARS-COV-2 (2019-NCOV) MAIN PROTEASE AND TERT-BUTYL (1-((S)-1-(((S)-4-(BENZYLAMINO)-3,4-DIOXO-1-((S)-2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)AMINO)-3-CYCLOPROPYL-1-OXOPROPAN-2-YL)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)CARBAMATE (ALPHA-KETOAMIDE 13B) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Y2K | CRYSTAL STRUCTURE OF BETA-GALACTOSIDASE FROM THE PSYCHROPHILIC MARINOMONAS EF1 | 3.2.1.23 |
| 6Y2V | CRYSTAL STRUCTURE OF THE DOUBLE MUTANT L13R I16K OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMW-PTP) | 3.1.3.48 3.1.3.2 |
| 6Y2W | CRYSTAL STRUCTURE OF THE SINGLE MUTANT I16K OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMW-PTP) | 3.1.3.48 3.1.3.2 |
| 6Y2Z | NG DOMAIN OF HUMAN SRP54 | 3.6.5 |
| 6Y30 | NG DOMAIN OF HUMAN SRP54 T115A MUTANT | 3.6.5 |
| 6Y31 | NG DOMAIN OF HUMAN SRP54 T117 DELETION MUTANT | 3.6.5 |
| 6Y32 | STRUCTURE OF THE GTPASE HETERODIMER OF HUMAN SRP54 AND SRALPHA | 3.6.5 |
| 6Y3B | CRYSTAL STRUCTURE OF UNLINKED NS2B-NS3 PROTEASE FROM ZIKA VIRUS IN COMPLEX WITH INHIBITOR MI-2110 | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 6Y3Y | HUMAN CORONAVIRUS HKU1 HAEMAGGLUTININ-ESTERASE | 3.1.1.53 |
| 6Y3Z | CRYSTAL STRUCTURE OF THE PBY1 ATP-GRASP ENZYME BOUND TO THE S. CEREVISIAE MRNA DECAPPING COMPLEX (DCP1-DCP2-EDC3) | 3.6.1.62 |
| 6Y4S | HUMAN KALLIKREIN-RELATED PEPTIDASE 7 (KLK7) IN THE UNLIGANDED STATE | 3.4.21.117 |
| 6Y4Z | THE CRYSTAL STRUCTURE OF HUMAN MACROD2 IN SPACE GROUP P43212 | 3.5.1 3.2.2 |
| 6Y5M | CRYSTAL STRUCTURE OF MOUSE AUTOTAXIN IN COMPLEX WITH COMPOUND 1A | 3.1.4.39 |
| 6Y5S | CRYSTAL STRUCTURE OF SAVINASE AT CRYOGENIC CONDITIONS | 3.4.21.62 |
| 6Y5T | CRYSTAL STRUCTURE OF SAVINASE AT ROOM TEMPERATURE | 3.4.21.62 |
| 6Y6L | STRUCTURE THE ANANAIN PROTEASE FROM ANANAS COMOSUS WITH A THIOMETHYLATED CATALYTIC CYSTEINE | 3.4.22.31 |
| 6Y6S | MOUSE GALACTOCEREBROSIDASE COMPLEXED WITH GALACTO-NOEUROSTEGINE GNS AT PH 6.8 | 3.2.1.46 |
| 6Y6T | MOUSE GALACTOCEREBROSIDASE COMPLEXED WITH GALACTO-NOEUROSTEGINE GNS AT PH 4.6 | 3.2.1.46 |
| 6Y6U | STRUCTURE OF PSEUDOMONAS AERUGINOSA PENICILLIN-BINDING PROTEIN 3 (PBP3) IN COMPLEX WITH COMPOUND 6 | 3.4.16.4 |
| 6Y6Z | STRUCTURE OF PSEUDOMONAS AERUGINOSA PENICILLIN-BINDING PROTEIN 3 (PBP3) IN COMPLEX WITH COMPOUND 1 | 3.4.16.4 |
| 6Y73 | THE CRYSTAL STRUCTURE OF HUMAN MACROD2 IN SPACE GROUP P43 | 3.5.1 3.2.2 |
| 6Y84 | SARS-COV-2 MAIN PROTEASE WITH UNLIGANDED ACTIVE SITE (2019-NCOV, CORONAVIRUS DISEASE 2019, COVID-19) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Y9T | FAMILY GH13_31 ENZYME | 3.2.1.10 |
| 6Y9V | STRUCTURE OF THE NATIVE FULL-LENGTH HIV-1 CAPSID PROTEIN IN COMPLEX WITH CYCLOPHILIN A FROM HELICAL ASSEMBLY (-8,13) | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6Y9W | STRUCTURE OF THE NATIVE FULL-LENGTH HIV-1 CAPSID PROTEIN IN COMPLEX WITH CYCLOPHILIN A FROM HELICAL ASSEMBLY (-13,8) | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6Y9X | STRUCTURE OF THE NATIVE FULL-LENGTH HIV-1 CAPSID PROTEIN IN COMPLEX WITH CYCLOPHILIN A FROM HELICAL ASSEMBLY (-13,7) | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6Y9Y | STRUCTURE OF THE NATIVE FULL-LENGTH HIV-1 CAPSID PROTEIN IN COMPLEX WITH CYCLOPHILIN A FROM HELICAL ASSEMBLY (-7,13) | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6Y9Z | STRUCTURE OF THE NATIVE FULL-LENGTH HIV-1 CAPSID PROTEIN IN COMPLEX WITH CYCLOPHILIN A FROM HELICAL ASSEMBLY (-13,9) | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 6YA5 | 2009 H1N1 PA ENDONUCLEASE IN COMPLEX WITH LU2 | 3.1 |
| 6YB7 | SARS-COV-2 MAIN PROTEASE WITH UNLIGANDED ACTIVE SITE (2019-NCOV, CORONAVIRUS DISEASE 2019, COVID-19). | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YBF | RT STRUCTURE OF HEW LYSOZYME OBTAINED AT 1.13 A RESOLUTION FROM CRYSTAL GROWN IN A KAPTON MICROCHIP. | 3.2.1.17 |
| 6YBI | RT STRUCTURE OF HEW LYSOZYME OBTAINED AT 1.12 A RESOLUTION FROM CRYSTAL GROWN IN A MYLAR MICROCHIP. | 3.2.1.17 |
| 6YCB | STRUCTURE THE ANANAIN PROTEASE FROM ANANAS COMOSUS COVALENTLY BOUND TO WITH THE E64 INHIBITOR | 3.4.22.31 |
| 6YCC | STRUCTURE THE ANANAIN PROTEASE FROM ANANAS COMOSUS COVALENTLY BOUND TO THE E64 INHIBITOR | 3.4.22.31 |
| 6YCD | STRUCTURE THE ANANAIN PROTEASE FROM ANANAS COMOSUS COVALENTLY BOUND TO THE TLCK INHIBITOR | 3.4.22.31 |
| 6YDX | INSULIN-REGULATED AMINOPEPTIDASE COMPLEXED WITH A MACROCYCLIC PEPTIDIC INHIBITOR | 3.4.11.3 |
| 6YE1 | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH THE AMPCP DERIVATIVE A894 (COMPOUND 2N IN PUBLICATION) IN THE CLOSED FORM (CRYSTAL FORM IV) | 3.1.3.5 |
| 6YE2 | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH THE AMPCP DERIVATIVE A1202 (COMPOUND 4A IN PUBLICATION) IN THE CLOSED FORM (CRYSTAL FORM IV) | 3.1.3.5 |
| 6YEM | H1N1 2009 PA ENDONUCLEASE IN COMPLEX WITH QUAMBALARINE B | 3.1 |
| 6YEN | CRYSTAL STRUCTURE OF AMPC FROM E. COLI WITH TANIBORBACTAM (VNRX-5133) | 3.5.2.6 |
| 6YEO | CRYSTAL STRUCTURE OF AMPC FROM E. COLI WITH CYCLIC BORONATE 2 | 3.5.2.6 |
| 6YHH | X-RAY STRUCTURE OF FLAVOBACTERIUM JOHNSONIAE CHITOBIASE (FJGH20) | 3.2.1.52 |
| 6YHR | CRYSTAL STRUCTURE OF WERNER SYNDROME HELICASE | 3.6.4.12 3.1 |
| 6YHU | CRYSTAL STRUCTURE OF THE NSP7-NSP8 COMPLEX OF SARS-COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YHZ | UVRD HELICASE RNA POLYMERASE INTERACTIONS ARE GOVERNED BY UVRDS CARBOXY TERMINAL TUDOR DOMAIN. | 3.6.4 |
| 6YI2 | UVRD HELICASE RNA POLYMERASE INTERACTIONS ARE GOVERNED BY UVRDS CARBOXY TERMINAL TUDOR DOMAIN. | 3.6.4.12 |
| 6YIS | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YIT | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YIU | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YIV | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YIW | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YIX | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YIY | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YJX | STRUCTURE OF HEN EGG-WHITE LYSOZYME CRYSTALLIZED WITH PAS POLYPEPTIDE | 3.2.1.17 |
| 6YL4 | SOLUBLE EPOXIDE HYDROLASE IN COMPLEX WITH 3-((R)-3-(1-HYDROXYUREIDO)BUT-1-YN-1-YL)-N-((S)-3-PHENYL-3-(4-TRIFLUOROMETHOXY)PHENYL)PROPYL)BENZAMIDE | 3.3.2.10 3.1.3.76 |
| 6YN0 | STRUCTURE OF E. COLI PBP1B WITH A FTSN PEPTIDE ACTIVATING TRANSGLYCOSYLASE ACTIVITY | 2.4.1.129 3.4.16.4 |
| 6YN8 | HUMAN MALT1(334-719) IN COMPLEX WITH A TETRAZOLE CONTAINING COMPOUND | 3.4.22 |
| 6YN9 | MALT1(329-728) IN COMPLEX WITH A SULFONAMIDE CONTAINING COMPOUND | 3.4.22 |
| 6YNQ | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO 2-METHYL-1-TETRALONE. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YO9 | PRODUCT BOUND STRUCTURE OF THE ECTOINE UTILIZATION PROTEIN EUTD (DOEA) FROM HALOMONAS ELONGATA | 3.4 3.5.4.44 |
| 6YOB | STRUCTURE OF LYSOZYME FROM COC IMISX SETUP COLLECTED BY ROTATION SERIAL CRYSTALLOGRAPHY ON CRYSTALS PRELOCATED BY 2D X-RAY PHASE-CONTRAST IMAGING | 3.2.1.17 |
| 6YOC | STRUCTURE OF LYSOZYME FROM COC IMISX SETUP COLLECTED BY STILL SERIAL CRYSTALLOGRAPHY ON CRYSTALS PRELOCATED BY 2D X-RAY PHASE-CONTRAST IMAGING | 3.2.1.17 |
| 6YOD | STRUCTURE OF LYSOZYME FROM SIN IMISX SETUP COLLECTED BY ROTATION SERIAL CRYSTALLOGRAPHY ON CRYSTALS PRELOCATED BY 2D X-RAY PHASE-CONTRAST IMAGING | 3.2.1.17 |
| 6YOE | STRUCTURE OF LYSOZYME FROM SIN IMISX SETUP COLLECTED BY STILL SERIAL CRYSTALLOGRAPHY ON CRYSTALS PRELOCATED BY 2D X-RAY PHASE-CONTRAST IMAGING | 3.2.1.17 |
| 6YOM | CRYSTAL STRUCTURE OF TETRAMERIC HUMAN D137N-SAMHD1 (RESIDUES 109-626) WITH XTP, DATP, DCMPNPP, MN AND MG | 3.1.5 |
| 6YPB | NUDIX1 HYDROLASE FROM ROSA X HYBRIDA | 3.6.1.68 |
| 6YPD | CRYSTAL STRUCTURE OF AMPC FROM E. COLI WITH CYCLIC BORONATE 3 (CB3 / APC308) | 3.5.2.6 |
| 6YPF | NUDIX1 HYDROLASE FROM ROSA X HYBRIDA IN COMPLEX WITH GERANYL PYROPHOSPHATE | 3.6.1.68 |
| 6YPT | X-RAY STRUCTURE OF TURNIP YELLOW MOSAIC VIRUS PRO/DUB IN COMPLEX WITH UBIQUITIN | 2.1.1 3.4.22 3.6.4 2.7.7.48 |
| 6YQ7 | TAKA-AMYLASE | 3.2.1.1 |
| 6YR8 | AFFIMER K6 - KRAS PROTEIN COMPLEX | 3.6.5.2 |
| 6YSK | 1-PHENYLPYRROLES AND 1-ENYLPYRROLIDINES AS INHIBITORS OF NOTUM | 3.1.1.98 |
| 6YTS | SOLUTION NMR STRUCTURE OF TYPE-I RIBOSOME-INACTIVATING PROTEIN TRICHOBAKIN (TBK) | 3.2.2.22 |
| 6YUW | STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 454 | 3.1.1.98 |
| 6YUY | STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 471 | 3.1.1.98 |
| 6YV0 | STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLIDINE-3-CARBOXYLIC ACID FRAGMENT 587 | 3.1.1.98 |
| 6YV2 | STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLIDINE-3-CARBOXYLIC ACID FRAGMENT 598 | 3.1.1.98 |
| 6YV4 | STRUCTURE OF THE WNT DEACYLASE NOTUM IN COMPLEX WITH A PYRROLE-3-CARBOXYLIC ACID FRAGMENT 686 | 3.1.1.98 |
| 6YVA | PLPRO-C111S WITH MISG15 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YVF | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO AZD6482. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YWK | CRYSTAL STRUCTURE OF SARS-COV-2 (COVID-19) NSP3 MACRODOMAIN IN COMPLEX WITH HEPES | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YWL | CRYSTAL STRUCTURE OF SARS-COV-2 (COVID-19) NSP3 MACRODOMAIN IN COMPLEX WITH ADP-RIBOSE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YWM | CRYSTAL STRUCTURE OF SARS-COV-2 (COVID-19) NSP3 MACRODOMAIN IN COMPLEX WITH MES | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YXI | STRUCTURE OF NOTUM IN COMPLEX WITH A 1-(3-CHLOROPHENYL)-2,5-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID INHIBITOR | 3.1.1.98 |
| 6YXQ | CRYSTAL STRUCTURE OF A DNA REPAIR COMPLEX ASCC3-ASCC2 | 3.6.4.12 |
| 6YXW | AFFIMER K3 - KRAS PROTEIN COMPLEX | 3.6.5.2 |
| 6YYH | CRYSTAL STRUCTURE OF BETA-D-XYLOSIDASE FROM DICTYOGLOMUS THERMOPHILUM IN LIGAND-FREE FORM | 3.2.1.37 |
| 6YYT | STRUCTURE OF REPLICATING SARS-COV-2 POLYMERASE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YZ1 | THE CRYSTAL STRUCTURE OF SARS-COV-2 NSP10-NSP16 METHYLTRANSFERASE COMPLEX WITH SINEFUNGIN | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YZ6 | STRUCTURE OF THE HEMIACETAL COMPLEX BETWEEN THE SARS-COV-2 MAIN PROTEASE AND LEUPEPTIN | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6YZA | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6YZC | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6Z05 | CAMPYLOBACTER JEJUNI SERINE PROTEASE HTRA | 3.4.21.107 |
| 6Z0V | CRYOEM STRUCTURE OF THE CHIKUNGUNYA VIRUS NSP1 COMPLEX | 2.1.1 2.7.7 3.1.3.33 3.4.22 3.6.1.15 3.6.4.13 3.1.3.84 2.7.7.19 2.7.7.48 |
| 6Z1Y | CRYSTAL STRUCTURE OF TYPE-I RIBOSOME-INACTIVATING PROTEIN TRICHOBAKIN (TBK) | 3.2.2.22 |
| 6Z21 | CRYSTAL STRUCTURE OF DEACYLATION MUTANT KPC-2 (E166Q) | 3.5.2.6 |
| 6Z22 | CRYSTAL STRUCTURE OF DEACYLATION MUTANT KPC-4 (E166Q) | 3.5.2.6 |
| 6Z23 | ACYLENZYME COMPLEX OF CEFOTAXIME BOUND TO DEACYLATION MUTANT KPC-2 (E166Q) | 3.5.2.6 |
| 6Z24 | ACYLENZYME COMPLEX OF CEFTAZIDIME BOUND TO DEACYLATION MUTANT KPC-2 (E166Q) | 3.5.2.6 |
| 6Z25 | ACYLENZYME COMPLEX OF CEFTAZIDIME BOUND TO DEACYLATION MUTANT KPC-4 (E166Q) | 3.5.2.6 |
| 6Z28 | CARBOXYPEPTIDASE T MUTANT L254N WITH N-SULFAMOYL-L-GLUTAMIC ACID | 3.4.17.18 |
| 6Z3P | STRUCTURE OF EV71 IN COMPLEX WITH A PROTECTIVE ANTIBODY 38-3-11A FAB | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 6Z3Q | STRUCTURE OF EV71 IN COMPLEX WITH A PROTECTIVE ANTIBODY 38-1-10A FAB | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 6Z5T | SARS-COV-2 MACRODOMAIN IN COMPLEX WITH ADP-RIBOSE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Z6G | CRYO-EM STRUCTURE OF LA CROSSE VIRUS POLYMERASE AT PRE-INITIATION STAGE | 2.7.7.48 3.1 |
| 6Z6I | SARS-COV-2 MACRODOMAIN IN COMPLEX WITH ADP-HPD | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Z72 | SARS-COV-2 MACRODOMAIN IN COMPLEX WITH ADP-HPM | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6Z80 | STIMULATORY HUMAN GTP CYCLOHYDROLASE I - GFRP COMPLEX | 3.5.4.16 |
| 6Z85 | INHIBITORY HUMAN GTP CYCLOHYDROLASE I - GFRP COMPLEX | 3.5.4.16 |
| 6Z87 | HUMAN GTP CYCLOHYDROLASE I | 3.5.4.16 |
| 6Z88 | HUMAN GTP CYCLOHYDROLASE I IN COMPLEX WITH ALLOSTERIC INHIBITOR | 3.5.4.16 |
| 6Z89 | HUMAN GTP CYCLOHYDROLASE I IN COMPLEX WITH ALLOSTERIC INHIBITOR | 3.5.4.16 |
| 6Z8K | LA CROSSE VIRUS POLYMERASE AT ELONGATION MIMICKING STAGE | 2.7.7.48 3.1 |
| 6Z8L | ALPHA-AMYLASE IN COMPLEX WITH PROBE FRAGMENTS | 3.2.1.1 |
| 6Z9B | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH AOPCP DERIVATIVE A830 (COMPOUND 16 IN PUBLICATION) IN THE CLOSED FORM (CRYSTAL FORM III) | 3.1.3.5 |
| 6Z9D | HUMAN ECTO-5'-NUCLEOTIDASE (CD73) IN COMPLEX WITH AOPCP DERIVATIVE AB680 (COMPOUND 55 IN PUBLICATION) IN THE CLOSED FORM (CRYSTAL FORM III) | 3.1.3.5 |
| 6ZB8 | EXO-BETA-1,3-GLUCANASE FROM MOOSE RUMEN MICROBIOME, ACTIVE SITE MUTANT E167Q/E295Q | 3.2.1.58 |
| 6ZB9 | EXO-BETA-1,3-GLUCANASE FROM MOOSE RUMEN MICROBIOME, WILD TYPE | 3.2.1.58 |
| 6ZCT | NONSTRUCTURAL PROTEIN 10 (NSP10) FROM SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6ZDC | STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN ENDO-ALPHA-MANNOSIDASE MANEA IN COMPLEX WITH NICKEL | 3.2.1.130 |
| 6ZDF | STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN ENDO-ALPHA-MANNOSIDASE MANEA IN COMPLEX WITH HEPES | 3.2.1.130 |
| 6ZE8 | CRYSTAL STRUCTURE OF HUMAN CHITOTRIOSIDASE-1 (HCHIT) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND OATD-01 | 3.2.1.14 |
| 6ZEF | STRUCTURE OF PP1(7-300) BOUND TO PHACTR1 (516-580) AT PH 5.25 | 3.1.3.16 |
| 6ZEG | STRUCTURE OF PP1-IRSP53 CHIMERA [PP1(7-304) + LINKER (G/S)X9 + IRSP53(449-465)] BOUND TO PHACTR1 (516-580) | 3.1.3.16 |
| 6ZEH | STRUCTURE OF PP1-SPECTRIN ALPHA II CHIMERA [PP1(7-304) + LINKER (G/S)X9 + SPECTRIN ALPHA II (1025-1039)] BOUND TO PHACTR1 (516-580) | 3.1.3.16 |
| 6ZEI | STRUCTURE OF PP1-IRSP53 S455E CHIMERA [PP1(7-304) + LINKER (G/S)X9 + IRSP53(449-465)] BOUND TO PHACTR1 (516-580) | 3.1.3.16 |
| 6ZEJ | STRUCTURE OF PP1-PHACTR1 CHIMERA [PP1(7-304) + LINKER (SGSGS) + PHACTR1(526-580)] | 3.1.3.16 |
| 6ZFJ | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6ZFK | TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN | 3.4.21.4 |
| 6ZFX | HSARM1 GRAFIX-ED | 3.2.2.6 3.2.2 |
| 6ZG0 | SARM1 SAM1-2 DOMAINS | 3.2.2.6 3.2.2 |
| 6ZG1 | SARM1 SAM1-2 DOMAINS | 3.2.2.6 3.2.2 |
| 6ZGH | FURIN CLEAVED SPIKE PROTEIN OF SARS-COV-2 IN INTERMEDIATE CONFORMATION | 3.1.3.48 |
| 6ZIO | CRYSTAL STRUCTURE OF NRAS (C118S) IN COMPLEX WITH GDP | 3.6.5.2 |
| 6ZIR | CRYSTAL STRUCTURE OF NRAS (C118S) IN COMPLEX WITH GDP AND COMPOUND 18 | 3.6.5.2 |
| 6ZIZ | CRYSTAL STRUCTURE OF NRAS Q61R IN COMPLEX WITH GTP AND COMPOUND 18 | 3.6.5.2 |
| 6ZJ0 | CRYSTAL STRUCTURE OF HRAS-G12D IN COMPLEX WITH GCP AND COMPOUND 18 | 3.6.5.2 |
| 6ZJA | HELICOBACTER PYLORI UREASE WITH INHIBITOR BOUND IN THE ACTIVE SITE | 3.5.1.5 |
| 6ZJP | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT E517Q | 3.2.1.23 |
| 6ZJQ | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT E517Q IN COMPLEX WITH GALACTOSE | 3.2.1.23 |
| 6ZJR | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT E517Q IN COMPLEX WITH LACTULOSE | 3.2.1.23 |
| 6ZJS | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT E441Q IN COMPLEX WITH GALACTOSE | 3.2.1.23 |
| 6ZJT | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT E441Q IN COMPLEX WITH LACTULOSE | 3.2.1.23 |
| 6ZJU | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT E441Q IN COMPLEX WITH SACCHAROSE | 3.2.1.23 |
| 6ZJV | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT D207A | 3.2.1.23 |
| 6ZJW | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT D207A IN COMPLEX WITH GALACTOSE | 3.2.1.23 |
| 6ZJX | COLD-ADAPTED BETA-D-GALACTOSIDASE FROM ARTHROBACTER SP. 32CB MUTANT D207A IN COMPLEX WITH SACCHAROSE | 3.2.1.23 |
| 6ZK6 | PROTEIN PHOSPHATASE 1 (PP1) T320E MUTANT | 3.1.3.16 |
| 6ZL3 | CRYSTAL STRUCTURE OF HRAS IN COMPLEX WITH COMPOUND 18 AND GDP | 3.6.5.2 |
| 6ZL5 | CRYSTAL STRUCTURE OF KRAS-G12D(C118S) IN COMPLEX WITH BI-2852 AND GDP | 3.6.5.2 |
| 6ZL7 | CRYSTAL STRUCTURE OF C173S MUTATION IN THE PMGL2 ESTERASE FROM PERMAFROST METAGENOMIC LIBRARY | 3.1.1.3 |
| 6ZLI | CRYSTAL STRUCTURE OF KRAS-G12D IN COMPLEX WITH COMPOUND 13 AND GCP | 3.6.5.2 |
| 6ZN8 | CRYSTAL STRUCTURE OF THE H. INFLUENZAE VAPXD TOXIN-ANTITOXIN COMPLEX | 3.1 |
| 6ZND | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE PHOSPHODIESTERASE 2 INHIBITORS | 3.1.4.17 |
| 6ZNP | CRYSTAL STRUCTURE OF DUF1998 HELICASE MRFA BOUND TO DNA | 3.6.4 |
| 6ZNQ | CRYSTAL STRUCTURE OF DUF1998 HELICASE MRFA BOUND TO DNA AND AMPPNP | 3.6.4 |
| 6ZNS | CRYSTAL STRUCTURE OF DUF1998 HELICASE MRFA | 3.6.4 |
| 6ZOV | ENTEROPEPTIDASE IN COMPLEX WITH COMPOUND 6 | 3.4.21.9 |
| 6ZPE | NONSTRUCTURAL PROTEIN 10 (NSP10) FROM SARS COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6ZPU | CRYSTAL STRUCTURE OF ANGIOTENSIN-1 CONVERTING ENZYME C-DOMAIN WITH INSERTED SYMMETRY MOLECULE C-TERMINUS. | 3.2.1 3.4.15.1 |
| 6ZQI | CRYO-EM STRUCTURE OF SPONDWENI VIRUS PRME | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 6ZQJ | CRYO-EM STRUCTURE OF TRIMERIC PRME SPIKE OF SPONDWENI VIRUS | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 6ZQT | CRYSTAL STRUCTURE OF THE RLIP76 RAL BINDING DOMAIN MUTANT (E427H/Q433L/K440R) IN COMPLEX WITH RALB-GMPPNP | 3.6.5.2 |
| 6ZQU | CRYO-EM STRUCTURE OF MATURE DENGUE VIRUS 2 AT 3.1 ANGSTROM RESOLUTION | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 6ZQV | CRYO-EM STRUCTURE OF MATURE SPONDWENI VIRUS | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 6ZQW | CRYO-EM STRUCTURE OF IMMATURE SPONDWENI VIRUS | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 6ZQZ | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE PHOSPHODIESTERASE 2 INHIBITORS | 3.1.4.17 |
| 6ZRN | CRYSTAL STRUCTURE OF THE RLIP76 RAL BINDING DOMAIN MUTANT (E427S/L429M/Q433L/K440R) IN COMPLEX WITH RALB-GMPPNP | 3.6.5.2 |
| 6ZRT | CRYSTAL STRUCTURE OF SARS COV2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR TELAPREVIR | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6ZRU | CRYSTAL STRUCTURE OF SARS COV2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR BOCEPREVIR | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 6ZS2 | CRYSTAL STRUCTURE OF THE BROMODOMAIN OF HUMAN TRANSCRIPTION ACTIVATOR BRG1 (SMARCA4) IN COMPLEX WITH 2-(6-AMINO-5-(PIPERAZIN-1-YL)PYRIDAZIN-3-YL)PHENOL | 3.6.4 |
| 6ZTS | ASSEMBLY INTERMEDIATES OF ORTHOREOVIRUS CAPTURED IN THE CELL | 3.6.4.13 |
| 6ZTZ | ASSEMBLY INTERMEDIATES OF ORTHOREOVIRUS CAPTURED IN THE CELL | 3.6.4.13 |
| 6ZUG | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND10 | 3.4.21.5 |
| 6ZUH | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND17 | 3.4.21.5 |
| 6ZUN | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND20A | 3.4.21.5 |
| 6ZUU | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND30 | 3.4.21.5 |
| 6ZUV | NOTUM FRAGMENT 286 | 3.1.1.98 |
| 6ZUW | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND40 | 3.4.21.5 |
| 6ZUX | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND42A | 3.4.21.5 |
| 6ZV7 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND42B | 3.4.21.5 |
| 6ZV8 | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND51 | 3.4.21.5 |
| 6ZVL | ARUK3000263 COMPLEX WITH NOTUM | 3.1.1.98 |
| 6ZYH | CRYSTAL STRUCTURE OF GRP78 (70KDA HEAT SHOCK PROTEIN 5 / BIP) ATPASE DOMAIN IN COMPLEX WITH ADP AND CALCIUM | 3.6.4.10 |
| 6ZYP | STRUCTURE OF NDM-1 WITH 2-MERCAPTOMETHYL-THIAZOLIDINE L-ANTI-1B | 3.5.2.6 |
| 6ZYQ | STRUCTURE OF NDM-1 WITH 2-MERCAPTOMETHYL-THIAZOLIDINE D-SYN-1B | 3.5.2.6 |
| 6ZYR | STRUCTURE OF IMP-1 WITH 2-MERCAPTOMETHYL-THIAZOLIDINE L-ANTI-1B | 3.5.2.6 |
| 6ZYS | STRUCTURE OF IMP-1 WITH 2-MERCAPTOMETHYL-THIAZOLIDINE D-SYN-1B | 3.5.2.6 |
| 721P | THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES | 3.6.5.2 |
| 7A0V | CRYSTAL STRUCTURE OF THE 5-PHOSPHATASE DOMAIN OF SYNAPTOJANIN1 IN COMPLEX WITH A NANOBODY | 3.1.3.36 |
| 7A12 | CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GW557358X (COMPOUND 9) | 3.4.11.18 |
| 7A13 | CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK1978537A (COMPOUND 27) | 3.4.11.18 |
| 7A14 | CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2218325A (COMPOUND 32) | 3.4.11.18 |
| 7A15 | CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2224863A (COMPOUND 42) | 3.4.11.18 |
| 7A16 | CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX WITH AN INHIBITOR GSK2229238A (COMPOUND 43) | 3.4.11.18 |
| 7A17 | CRYSTAL STRUCTURE OF THE 5-PHOSPHATASE DOMAIN OF SYNAPTOJANIN1 BOUND TO ITS SUBSTRATE DIC8-PI(3,4,5)P3 IN COMPLEX WITH A NANOBODY | 3.1.3.36 |
| 7A1F | CRYSTAL STRUCTURE OF HUMAN 5' EXONUCLEASE APPOLLO IN COMPLEX WITH 5'DAMP | 3.1 |
| 7A1U | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO FUSIDIC ACID. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7A3H | NATIVE ENDOGLUCANASE CEL5A CATALYTIC CORE DOMAIN AT 0.95 ANGSTROMS RESOLUTION | 3.2.1.4 |
| 7A41 | MALT1 IN COMPLEX WITH A NVS-MALT1 CHEMICAL PROBE | 3.4.22 |
| 7A4U | CRYSTAL STRUCTURE OF LID-TRUNCATED APO BIP IN AN OLIGOMERIC STATE | 3.6.4.10 |
| 7A4V | CRYSTAL STRUCTURE OF LID-TRUNCATED ADP-BOUND BIP IN AN OLIGOMERIC STATE | 3.6.4.10 |
| 7A54 | TWO COPIES OF THE CATALYTIC DOMAIN OF NANA SIALIDASE FROM STREPTOCOCCUS PNEUMONIAE JUXTAPOSED IN THE P212121 SPACE GROUP, IN COMPLEX WITH DANA | 3.2.1.18 |
| 7A5X | TWO COPIES OF THE CATALYTIC DOMAIN OF NANA SIALIDASE FROM STREPTOCOCCUS PNEUMONIAE JUXTAPOSED IN THE P212121 SPACE GROUP, IN COMPLEX WITH DANA DERIVATIZED WITH A PEG LINKER ON THE GLYCEROL GROUP. | 3.2.1.18 |
| 7A68 | PROTEINASE K CRYSTALLIZED FROM 0.5 M NANO3 | 3.4.21.64 |
| 7A70 | HEW LYSOZYME IN COMPLEX WITH TI(OH)4 | 3.2.1.17 |
| 7AAP | NSP7-NSP8-NSP12 SARS-COV2 RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH TEMPLATE:PRIMER DSRNA AND FAVIPIRAVIR-RTP | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ABU | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO RS102895 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ACA | CRYSTAL STRUCTURE OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747 | 3.6.5.2 |
| 7ACF | CRYSTAL STRUCTURE OF CRYSTAL FORM 2 OF AN ACTIVE KRAS G12D (GPPCP) DIMER IN COMPLEX WITH BI-5747 | 3.6.5.2 |
| 7ACH | CRYSTAL STRUCTURE OF ACTIVE KRAS G12D (GPPCP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747 | 3.6.5.2 |
| 7ACQ | CRYSTAL STRUCTURE OF INACTIVE KRAS G12D (GDP) IN COMPLEX WITH THE SOAKED DIMERIC INHIBITOR BI-5747 | 3.6.5.2 |
| 7ADW | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO 2,4'-DIMETHYLPROPIOPHENONE. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AF0 | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO IPIDACRINE. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AF1 | THE STRUCTURE OF ARTEMIS/SNM1C/DCLRE1C WITH 2 ZINC IONS | 3.1 |
| 7AFS | THE STRUCTURE OF ARTEMIS VARIANT D37A | 3.1 |
| 7AFU | THE STRUCTURE OF ARTEMIS VARIANT H33A | 3.1 |
| 7AGA | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO AT7519 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AGI | THE STRUCTURE OF ARTEMIS VARIANT H35D | 3.1 |
| 7AGM | CRYSTAL STRUCTURE OF THE N-ACETYLMURAMYL-L-ALANINE AMIDASE, AMI1, FROM MYCOBACTERIUM SMEGMATIS | 3.5.1.28 |
| 7AHA | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO MALEATE. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AHO | RUVBL1-RUVBL2 HETEROHEXAMERIC RING AFTER BINDING OF RNA HELICASE DHX34 | 3.6.4.12 |
| 7AHX | HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND D-ASPARTATE TENOFOVIR WITH BOUND MANGANESE | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7AID | HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND D-ASPARTATE TENOFOVIR | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7AIF | HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-GLUTAMATE TENOFOVIR WITH BOUND MANGANESE | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7AIG | HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-GLUTAMATE TENOFOVIR | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7AII | HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-METHIONINE TENOFOVIR WITH BOUND MANGANESE | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7AIJ | HIV-1 REVERSE TRANSCRIPTASE COMPLEX WITH DNA AND L-METHIONINE TENOFOVIR | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7AK0 | HUMAN MALT1(329-729) IN COMPLEX WITH A CHROMANE UREA CONTAINING INHIBITOR | 3.4.22 |
| 7AK1 | HUMAN MALT1(329-729) IN COMPLEX WITH A CHROMANE UREA CONTAINING INHIBITOR | 3.4.22 |
| 7AKN | THERMOLYSIN FROM BACILLUS THERMOPROTEOLYTICUS | 3.4.24.27 |
| 7AKU | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO CALPEPTIN. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ALH | CRYSTAL STRUCTURE OF THE MAIN PROTEASE (3CLPRO/MPRO) OF SARS-COV-2 AT 1.65A RESOLUTION (SPACEGROUP C2). | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ALI | CRYSTAL STRUCTURE OF THE MAIN PROTEASE (3CLPRO/MPRO) OF SARS-COV-2 AT 1.65A RESOLUTION (SPACEGROUP P2(1)). | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AMJ | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO PD 168568. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ANS | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO ADRAFINIL. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AOL | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO CLIMBAZOLE | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 7AP6 | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO MUT056399. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7APV | STRUCTURE OF ARTEMIS/DCLRE1C/SNM1C IN COMPLEX WITH CEFTRIAXONE | 3.1 |
| 7AQI | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO IFENPRODIL | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AQJ | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO TRIGLYCIDYL ISOCYANURATE. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AQP | T262S, A251S, L254S, L211Q MUTANT OF CARBOXYPEPTIDASE T FROM THERMOACTINOMYCES VULGARIS | 3.4.17.18 |
| 7AR5 | STRUCTURE OF APO SARS-COV-2 MAIN PROTEASE WITH SMALL BETA ANGLE, SPACE GROUP C2. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AR6 | STRUCTURE OF APO SARS-COV-2 MAIN PROTEASE WITH LARGE BETA ANGLE, SPACE GROUP C2. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ARF | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO THIOGLUCOSE. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7ARU | L254N MUTANT OF CARBOXYPEPTIDASE T FROM THERMOACTINOMYCES VULGARIS N-SULFAMOYL-L-VALINE | 3.4.17.18 |
| 7ASS | OXA-48_L67F_CAZ. WHAT DOESNT KILL YOU MAKES YOU STRONGER: SUB-MIC SELECTION DRIVES CRYPTIC EVOLUTION OF OXA-48 | 3.5.2.6 |
| 7AUC | CRYSTAL STRUCTURE OF AN ENGINEERED HELICASE DOMAIN CONSTRUCT FOR HUMAN BLOOM SYNDROME PROTEIN (BLM) | 3.6.4.12 |
| 7AUD | STRUCTURE OF AN ENGINEERED HELICASE DOMAIN CONSTRUCT FOR HUMAN BLOOM SYNDROME PROTEIN (BLM) | 3.6.4.12 |
| 7AVD | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO SEN1269 LIGAND | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AVM | CRYSTAL STRUCTURE OF PRO-RHODESAIN C150A | 3.4.22.15 |
| 7AWR | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO TEGAFUR | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AWS | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO TH-302. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AWU | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO LSN2463359. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AWW | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO CLONIDINE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AX6 | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO GLUTATHIONE ISOPROPYL ESTER | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AX7 | CRYSTAL STRUCTURE OF THE XYL-CE4 DOMAIN OF A MULTIDOMAIN XYLANASE FROM THE HINDGUT METAGENOME OF TRINERVITERMES TRINERVOIDES | 3.2.1.8 |
| 7AXM | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO PELITINIB | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AXO | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO AR-42. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AY3 | CRYSTAL STRUCTURE OF THE CBM36-1 DOMAIN OF A MULTIDOMAIN XYLANASE FROM THE HINDGUT METAGENOME OF TRINERVITERMES TRINERVOIDES | 3.2.1.8 |
| 7AY7 | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO ISOFLOXYTHEPIN | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7AYL | CRYSTAL STRUCTURE OF THE GH11 DOMAIN OF A MULTIDOMAIN XYLANASE FROM THE HINDGUT METAGENOME OF TRINERVITERMES TRINERVOIDES | 3.2.1.8 |
| 7AYP | STRUCTURE OF A GH11 DOMAIN REFINED FROM THE X-RAY DIFFRACTION DATA OF A GH11-CBM36-1 CRYSTAL. | 3.2.1.8 |
| 7AYS | STRUCTURE OF BOVINE TRYPSIN DETERMINED FROM SINGLE FEMTOSECOND SNAPSHOTS PER ORIENTATION AT ROOM TEMPERATURE | 3.4.21.4 |
| 7B2X | CRYSTAL STRUCTURE OF HUMAN 5' EXONUCLEASE APPOLLO H61Y VARIANT | 3.1 |
| 7B3B | STRUCTURE OF ELONGATING SARS-COV-2 RNA-DEPENDENT RNA POLYMERASE WITH REMDESIVIR AT POSITION -3 (STRUCTURE 1) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7B3C | STRUCTURE OF ELONGATING SARS-COV-2 RNA-DEPENDENT RNA POLYMERASE WITH REMDESIVIR AT POSITION -4 (STRUCTURE 2) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7B3D | STRUCTURE OF ELONGATING SARS-COV-2 RNA-DEPENDENT RNA POLYMERASE WITH AMP AT POSITION -4 (STRUCTURE 3) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7B3E | CRYSTAL STRUCTURE OF MYRICETIN COVALENTLY BOUND TO THE MAIN PROTEASE (3CLPRO/MPRO) OF SARS-COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7B83 | STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO PYRITHIONE ZINC | 2.7.7.48 3.4.19.12 3.4.22.69 3.6.4.12 3.6.4.13 |
| 7B9B | CRYSTAL STRUCTURE OF HUMAN 5' EXONUCLEASE APPOLLO APO FORM | 3.1 |
| 7BF3 | CRYSTAL STRUCTURE OF SARS-COV-2 MACRODOMAIN IN COMPLEX WITH ADENOSINE | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BF4 | CRYSTAL STRUCTURE OF SARS-COV-2 MACRODOMAIN IN COMPLEX WITH GMP | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BF5 | CRYSTAL STRUCTURE OF SARS-COV-2 MACRODOMAIN IN COMPLEX WITH ADP-RIBOSE-PHOSPHATE (ADP-RIBOSE-2'-PHOSPHATE, ADPRP) | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BF6 | CRYSTAL STRUCTURE OF SARS-COV-2 MACRODOMAIN IN COMPLEX WITH REMDESIVIR METABOLITE GS-441524 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BPI | THE CRYSTAL STRUCTUE OF PDE10A COMPLEXED WITH 14 | 3.1.4.17 3.1.4.35 |
| 7BQ7 | CRYSTAL STRUCTURE OF 2019-NCOV NSP16-NSP10 COMPLEX | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BQY | THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH AN INHIBITOR N3 AT 1.7 ANGSTROM | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BRO | CRYSTAL STRUCTURE OF THE 2019-NCOV MAIN PROTEASE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BRP | CRYSTAL STRUCTURE OF THE 2019-NCOV MAIN PROTEASE COMPLEXED WITH BOCEPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BRV | BOVINE PANCREATIC TRYPSIN WITH 4-BROMOBENZAMIDINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BRW | BOVINE PANCREATIC TRYPSIN WITH 5-CHLOROTRYPTAMINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BRX | BOVINE PANCREATIC TRYPSIN WITH 5-METHOXYTRYPTAMINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BRY | BOVINE PANCREATIC TRYPSIN WITH 6-METHOXYTRYPTAMINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BRZ | BOVINE PANCREATIC TRYPSIN WITH 2-METHYLTRYPTAMINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BS0 | BOVINE PANCREATIC TRYPSIN WITH ANILINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BS1 | BOVINE PANCREATIC TRYPSIN WITH BENZAMIDINE (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BS2 | BOVINE PANCREATIC TRYPSIN WITH SEROTONIN (ROOM TEMPERATURE) | 3.4.21.4 |
| 7BS3 | BOVINE PANCREATIC TRYPSIN WITH 4-BROMO-BENZAMIDINE (CRYO) | 3.4.21.4 |
| 7BS4 | BOVINE PANCREATIC TRYPSIN WITH 5-METHOXYTRYPTAMINE (CRYO) | 3.4.21.4 |
| 7BS5 | BOVINE PANCREATIC TRYPSIN WITH 6-METHOXYTRYPTAMINE (CRYO) | 3.4.21.4 |
| 7BS6 | BOVINE PANCREATIC TRYPSIN WITH 2-METHYLTRYPTAMINE (CRYO) | 3.4.21.4 |
| 7BS7 | BOVINE PANCREATIC TRYPSIN WITH ANILINE (CRYO) | 3.4.21.4 |
| 7BS8 | BOVINE PANCREATIC TRYPSIN WITH BENZAMIDINE (CRYO) | 3.4.21.4 |
| 7BS9 | BOVINE PANCREATIC TRYPSIN WITH SEROTONIN (CRYO) | 3.4.21.4 |
| 7BSA | BOVINE PANCREATIC TRYPSIN WITH 5-CHLOROTRYPTAMINE (CRYO) | 3.4.21.4 |
| 7BTF | SARS-COV-2 RNA-DEPENDENT RNA POLYMERASE IN COMPLEX WITH COFACTORS IN REDUCED CONDITION | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BTG | CRYSTAL STRUCTURE OF DARP, DROSOPHILA ARGININE PHOSPHATASE | 3.1.3.2 |
| 7BTN | CRYSTAL STRUCTURE OF HUMAN INORGANIC PYROPHOSPHATASE WITH METAL IONS | 3.6.1.1 |
| 7BTP | ECOR124I-OCR IN RESTRICTION-ALLEVIATION STATE | 3.1.21.3 |
| 7BTS | STRUCTURE OF HUMAN BETA1 ADRENERGIC RECEPTOR BOUND TO EPINEPHRINE AND NANOBODY 6B9 | 3.2.1.17 |
| 7BU6 | STRUCTURE OF HUMAN BETA1 ADRENERGIC RECEPTOR BOUND TO NOREPINEPHRINE AND NANOBODY 6B9 | 3.2.1.17 |
| 7BU7 | STRUCTURE OF HUMAN BETA1 ADRENERGIC RECEPTOR BOUND TO BI-167107 AND NANOBODY 6B9 | 3.2.1.17 |
| 7BUY | THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH CARMOFUR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BV1 | CRYO-EM STRUCTURE OF THE APO NSP12-NSP7-NSP8 COMPLEX | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BV2 | THE NSP12-NSP7-NSP8 COMPLEX BOUND TO THE TEMPLATE-PRIMER RNA AND TRIPHOSPHATE FORM OF REMDESIVIR(RTP) | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BV5 | CRYSTAL STRUCTURE OF THE YEAST HETERODIMERIC ADAT2/3 | 3.5.4.33 |
| 7BVM | CRYSTAL STRUCTURE OF LYSOZYME DELIVERED IN WHEAT STARCH | 3.2.1.17 |
| 7BVO | CRYSTAL STRUCTURE OF LYSOZYME DELIVERED IN ALGINATE | 3.2.1.17 |
| 7BVQ | STRUCTURE OF HUMAN BETA1 ADRENERGIC RECEPTOR BOUND TO CARAZOLOL | 3.2.1.17 |
| 7BW4 | STRUCTURE OF THE RNA-DEPENDENT RNA POLYMERASE FROM SARS-COV-2 | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BWB | BOMBYX MORI GH32 BETA-FRUCTOFURANOSIDASE BMSUC1 | 3.2.1.26 |
| 7BWC | BOMBYX MORI GH32 BETA-FRUCTOFURANOSIDASE BMSUC1 MUTANT D63A IN COMPLEX WITH SUCROSE | 3.2.1.26 |
| 7BWG | A GLYCOSIDE HYDROLASE FAMILY 20 BETA-N-ACETYLGLUCOSAMINIDASE | 3.2.1.52 |
| 7BYS | CRYSTAL STRUCTURE OF EXO-BETA-1,3-GALACTANASE FROM PHANEROCHAETE CHRYSOSPORIUM PC1,3GAL43A APO FORM | 3.2.1.145 |
| 7BYT | CRYSTAL STRUCTURE OF EXO-BETA-1,3-GALACTANASE FROM PHANEROCHAETE CHRYSOSPORIUM PC1,3GAL43A WITH GALACTOSE | 3.2.1.145 |
| 7BYV | CRYSTAL STRUCTURE OF EXO-BETA-1,3-GALACTANASE FROM PHANEROCHAETE CHRYSOSPORIUM PC1,3GAL43A E208Q WITH BETA-1,3-GALACTOTRIOSE | 3.2.1.145 |
| 7BYX | CRYSTAL STRUCTURE OF EXO-BETA-1,3-GALACTANASE FROM PHANEROCHAETE CHRYSOSPORIUM PC1,3GAL43A E208A WITH BETA-1,3-GALACTOTRIOSE | 3.2.1.145 |
| 7BZF | COVID-19 RNA-DEPENDENT RNA POLYMERASE POST-TRANSLOCATED CATALYTIC COMPLEX | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7BZL | GH127 BETA-L-ARABINOFURANOSIDASE HYPBA1 COVALENTLY COMPLEXED WITH BETA-L-ARABINOFURANOSE-CONFIGURED CYCLOPHELLITOL | 3.2.1.185 |
| 7BZM | CRYSTAL STRUCTURE OF RICE OS3BGLU7 WITH GLUCOIMIDAZOLE | 3.2.1.21 |
| 7BZN | CRYO-EM STRUCTURE OF MATURE COXSACKIEVIRUS A10 AT PH 7.4 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7BZO | CRYO-EM STRUCTURE OF MATURE COXSACKIEVIRUS A10 AT PH 5.5 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7BZT | CRYO-EM STRUCTURE OF MATURE COXSACKIEVIRUS A10 IN COMPLEX WITH KRM1 AT PH 7.4 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7BZU | CRYO-EM STRUCTURE OF MATURE COXSACKIEVIRUS A10 IN COMPLEX WITH KRM1 AT PH 5.5 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C09 | STRUCTURE OF LYSOZYME OBTAINED IN SSRF USING SERIAL CRYSTALLOGRAPHY | 3.2.1.17 |
| 7C0I | CRYSTAL STRUCTURE OF CHIMERIC MUTANT OF E3L IN COMPLEX WITH Z-DNA | 3.5.4.37 |
| 7C0J | CRYSTAL STRUCTURE OF CHIMERIC MUTANT OF GH5 IN COMPLEX WITH Z-DNA | 3.5.4.37 |
| 7C0P | STRUCTURE OF PROTEINASE K OBTAINED IN SSRF USING SERIAL CRYSTALLOGRAPHY | 3.4.21.64 |
| 7C2I | CRYSTAL STRUCTURE OF NSP16-NSP10 HETERODIMER FROM SARS-COV-2 IN COMPLEX WITH SAM (WITH ADDITIONAL SAM DURING CRYSTALLIZATION) | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7C2J | CRYSTAL STRUCTURE OF NSP16-NSP10 HETERODIMER FROM SARS-COV-2 IN COMPLEX WITH SAM (WITHOUT ADDITIONAL SAM DURING CRYSTALLIZATION) | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7C2K | COVID-19 RNA-DEPENDENT RNA POLYMERASE PRE-TRANSLOCATED CATALYTIC COMPLEX | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C2M | CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS COMPLEXED WITH NITD-349 | 3.2.1.17 |
| 7C2N | CRYSTAL STRUCTURE OF MYCOLIC ACID TRANSPORTER MMPL3 FROM MYCOBACTERIUM SMEGMATIS COMPLEXED WITH SPIRO | 3.2.1.17 |
| 7C2Q | THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN THE APO STATE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C2S | HELICAL RECONSTRUCTION OF DENGUE VIRUS SEROTYPE 3 COMPLEXED WITH FAB C10 | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7C2T | HELICAL RECONSTRUCTION OF ZIKA VIRUS COMPLEXED WITH FAB C10 | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 7C2Y | THE CRYSTAL STRUCTURE OF COVID-2019 MAIN PROTEASE IN THE APO STATE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C33 | MACRO DOMAIN OF SARS-COV-2 IN COMPLEX WITH ADP-RIBOSE | 3.4.19.12 3.4.22 3.4.22.69 |
| 7C34 | CRYSTAL STRUCTURE OF SERRATIA MARCESCENS CHITINASE B COMPLEXED WITH BERBERINE | 3.2.1.14 |
| 7C4T | CRYO-EM STRUCTURE OF A PARTICLE COXSACKIEVIRUS A10 AT PH 7.4 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C4W | CRYO-EM STRUCTURE OF A PARTICLE COXSACKIEVIRUS A10 AT PH 5.5 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C4Y | CRYO-EM STRUCTURE OF EMPTY COXSACKIEVIRUS A10 AT PH 7.4 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C4Z | CRYO-EM STRUCTURE OF EMPTY COXSACKIEVIRUS A10 AT PH 5.5 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C62 | THE CRYSTAL STRUCTURE OF PARKINSON DISEASE PROTEIN 7 (DJ-1) FROM WUXI BIORTUS. | 3.1.2 3.5.1 3.5.1.124 |
| 7C6B | CRYSTAL STRUCTURE OF AGO2 MID DOMAIN IN COMPLEX WITH 6-(3-(2-CARBOXYETHYL)PHENYL)PURINE RIBOSIDE MONOPHOSPHATE | 3.1.26 |
| 7C6S | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE COMPLEXED WITH BOCEPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C6U | CRYSTAL STRUCTURE OF SARS-COV-2 COMPLEXED WITH GC376 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C7D | CRYSTAL STRUCTURE OF THE CATALYTIC UNIT OF THERMOSTABLE GH87 ALPHA-1,3-GLUCANASE FROM STREPTOMYCES THERMODIASTATICUS STRAIN HF3-3 | 3.2.1.59 |
| 7C7P | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH TELAPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C80 | E30 F-PARTICLE IN COMPLEX WITH 4B10 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C81 | E30 F-PARTICLE IN COMPLEX WITH 6C5 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C8B | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH Z-VAD(OME)-FMK | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C8D | CRYO-EM STRUCTURE OF CAT ACE2 AND SARS-COV-2 RBD | 3.4.17.23 3.4.17 |
| 7C8J | STRUCTURAL BASIS FOR CROSS-SPECIES RECOGNITION OF COVID-19 VIRUS SPIKE RECEPTOR BINDING DOMAIN TO BAT ACE2 | 3.4 |
| 7C8K | STRUCTURAL BASIS FOR CROSS-SPECIES RECOGNITION OF COVID-19 VIRUS SPIKE RECEPTOR BINDING DOMAIN TO BAT ACE2 | 3.4 |
| 7C8R | COMPLEX STRUCTURE OF SARS-COV-2 3CL PROTEASE WITH TG-0203770 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C8S | CRYSTAL STRUCTURE OF DUSP22 MUTANT_N128A | 3.1.3.16 3.1.3.48 |
| 7C8T | COMPLEX STRUCTURE OF SARS-COV-2 3CL PROTEASE WITH TG-0205221 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C8U | THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH GC376 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7C9S | ECHOVIRUS 30 F-PARTICLE | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C9T | ECHOVIRUS 30 A-PARTICLE | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C9U | ECHOVIRUS 30 E-PARTICLE | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C9V | E30 F-PARTICLE IN COMPLEX WITH FCRN | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C9W | E30 F-PARTICLE IN COMPLEX WITH CD55 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7C9Z | COXSACKIEVIRUS B1 F-PARTICLE | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7CBD | CATALYTIC DOMAIN OF CELLULOMONAS FIMI CEL6B | 3.2.1.91 |
| 7CBN | CRYSTAL STRUCTURE OF BETA-N-ACETYLHEXOSAMINIDASE AM0868 FROM AKKERMANSIA MUCINIPHILA | 3.2.1.52 |
| 7CBO | CRYSTAL STRUCTURE OF BETA-N-ACETYLHEXOSAMINIDASE AM0868 FROM AKKERMANSIA MUCINIPHILA IN COMPLEX WITH GLCNAC | 3.2.1.52 |
| 7CBQ | CRYSTAL STRUCTURE OF PDE4D CATALYTIC DOMAIN IN COMPLEX WITH APREMILAST | 3.1.4.53 |
| 7CBT | THE CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH GC376 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CD5 | MAPE1-BLUNT-ENDED DSDNA PRODUCT COMPLEX | 3.1 |
| 7CD6 | MAPE1-RECESSED DSDNA PRODUCT COMPLEX | 3.1 |
| 7CDH | CRYSTAL STRUCTURE OF BETAASPARTYL DIPEPTIDASE FROM THERMOPHILIC KERATIN DEGRADING FERVIDOBACTERIUM ISLANDICUM-AW-1 | 3.4.19 |
| 7CEF | CRYSTAL STRUCTURE OF PET-DEGRADING CUTINASE CUT190 /S226P/R228S/ MUTANT WITH THE C-TERMINAL THREE RESIDUES DELETION | 3.1.1.74 |
| 7CEH | CRYSTAL STRUCTURE OF PET-DEGRADING CUTINASE CUT190 S176A/S226P/R228S/ MUTANT WITH THE C-TERMINAL THREE RESIDUES DELETION IN LIGAND EJECTING FORM | 3.1.1.74 |
| 7CEL | CBH1 (E217Q) IN COMPLEX WITH CELLOHEXAOSE AND CELLOBIOSE | 3.2.1.91 |
| 7CFL | X-RAY STRUCTURE OF AUTOLYSIN ACD24020 CATALYTIC DOMAIN FROM CLOSTRIDIUM DIFFICILE | 3.4 |
| 7CI4 | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CI5 | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CI6 | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CI7 | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CI8 | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CI9 | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CIA | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CIB | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CIC | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CID | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CIE | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7CJ3 | CRYSTAL STRUCTURE OF THE TRANSMEMBRANE DOMAIN OF SALPINGOECA ROSETTA RHODOPSIN PHOSPHODIESTERASE | 3.1.4 |
| 7CJD | CRYSTAL STRUCTURE OF THE SARS-COV-2 PLPRO C111S MUTANT | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CJM | SARS COV-2 PLPRO IN COMPLEX WITH GRL0617 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CJU | CRYSTAL STRUCTURE OF INACTIVE FORM OF CHITOSANASE CRYSTALLIZED BY AMMONIUM SULFATE | 3.2.1 |
| 7CJZ | ROOM TEMPERATURE STRUCTURE OF LYSOZYME DELIVERED IN LARD BY SERIAL MILLISECOND CRYSTALLOGRAPHY | 3.2.1.17 |
| 7CM1 | NEURAMINIDASE FROM THE WUHAN ASIATIC TOAD INFLUENZA VIRUS | 3.2.1.18 |
| 7CM2 | THE CRYSTAL STRUCTURE OF HUMAN USP7 USP DOMAIN FROM WUXI BIORTUS. | 3.4.19.12 |
| 7CM5 | FULL-LENGTH SARM1 IN A SELF-INHIBITED STATE | 3.2.2.6 3.2.2 |
| 7CM7 | NAD+-BOUND SARM1 E642A IN THE SELF-INHIBITED STATE | 3.2.2.6 3.2.2 |
| 7CMD | CRYSTAL STRUCTURE OF THE SARS-COV-2 PLPRO WITH GRL0617 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CMK | E30 E-PARTICLE IN COMPLEX WITH 6C5 | 3.4.22.29 3.6.1.15 3.4.22.28 2.7.7.48 |
| 7CMO | CRYSTAL STRUCTURE OF HUMAN INORGANIC PYROPHOSPHATASE | 3.6.1.1 |
| 7CN7 | T4 PHAGE SPACKLE PROTEIN GP61.3 COMPLEX WITH LYSOZYME DOMAIN OF GP5 TAIL LYSOZYME | 3.2.1.17 |
| 7CNE | CRYSTAL STRUCTURE OF SPHINGOMYELINASE C FROM STREPTOMYCES GRISEOCARNEUS | 3.1.4.12 |
| 7COM | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH BOCEPREVIR (SPACE GROUP P212121) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CPA | COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY | 3.4.17.1 |
| 7CPK | XYLANASE R FROM BACILLUS SP. TAR-1 | 3.2.1.8 |
| 7CPL | XYLANASE R FROM BACILLUS SP. TAR-1 | 3.2.1.8 |
| 7CQY | TETRATHIONATE HYDROLASE FROM ACIDITHIOBACILLUS FERROOXIDANS MUTANT - D325N | 3.12.1 |
| 7CRB | CRYO-EM STRUCTURE OF PLANT NLR RPP1 LRR-ID DOMAIN IN COMPLEX WITH ATR1 | 3.2.2.6 |
| 7CRC | CRYO-EM STRUCTURE OF PLANT NLR RPP1 TETRAMER IN COMPLEX WITH ATR1 | 3.2.2.6 |
| 7CSN | CRYSTAL STRUCTURE OF PEPTIDYL-TRNA HYDROLASE FROM ACINETOBACTER BAUMANNII AT 1.00 A RESOLUTION | 3.1.1.29 |
| 7CTT | CRYO-EM STRUCTURE OF FAVIPIRAVIR BOUND TO REPLICATING POLYMERASE COMPLEX OF SARS-COV-2 IN THE PRE-CATALYTIC STATE. | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CUY | CRYSTAL STRUCTURE OF PRIMO-1 | 3.1.3.48 3.1.3.2 |
| 7CVJ | CRYSTAL STRUCTURE OF LYSOZYME BY FIXED-TARGET SERIAL SYNCHROTRON CRYSTALLOGRAPHY (100 MS) | 3.2.1.17 |
| 7CVL | CRYSTAL STRUCTURE OF LYSOZYME BY FIXED-TARGET SERIAL SYNCHROTRON CRYSTALLOGRAPHY (500 MS) | 3.2.1.17 |
| 7CVN | THE N-ARYLSULFONYL-INDOLE-2-CARBOXAMIDE-BASED INHIBITORS AGAINST FRUCTOSE-1,6-BISPHOSPHATASE | 3.1.3.11 |
| 7CWB | AMBIENT-TEMPERATURE SERIAL FEMTOSECOND X-RAY CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE AT 1.9 A RESOLUTION (C121) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CWC | AMBIENT-TEMPERATURE SERIAL FEMTOSECOND X-RAY CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE AT 2.1 A RESOLUTION (P212121) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CX9 | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INZ-1 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CXM | ARCHITECTURE OF A SARS-COV-2 MINI REPLICATION AND TRANSCRIPTION COMPLEX | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7CY3 | CRYSTAL STRUCTURE OF A BIODEGRADABLE PLASTIC-DEGRADING CUTINASE FROM PARAPHOMA SP. B47-9. | 3.1.1.74 |
| 7CY9 | CRYSTAL STRUCTURE OF A BIODEGRADABLE PLASTIC-DEGRADING CUTINASE FROM PARAPHOMA SP. B47-9 SOLVED BY GETTING THE PHASE FROM ANOMALOUS SCATTERING OF UNCOVALENTLY COORDINATED ARSENIC (CACODYLATE). | 3.1.1.74 |
| 7CYQ | CRYO-EM STRUCTURE OF AN EXTENDED SARS-COV-2 REPLICATION AND TRANSCRIPTION COMPLEX REVEALS AN INTERMEDIATE STATE IN CAP SYNTHESIS | 3.4.19.12 3.6.4.13 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.1.13 3.1 2.1.1 |
| 7CZ3 | CRYSTAL STRCUTURE OF ACYL-COA THIOESTERASE FROM BACILLUS CEREUS ATCC 14579 | 3.1.2.20 |
| 7CZ4 | STRUCTURE OF SARS-COV-2 MACRO DOMAIN IN COMPLEX WITH ADP-RIBOSE | 3.4.19.12 3.4.22 3.4.22.69 |
| 7D0W | CRYSTAL STRUCTURE OF HEN EGG WHITE LYSOZYME | 3.2.1.17 |
| 7D1M | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE COMPLEXED WITH GC376 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7D1O | CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE WITH NARLAPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7D3I | CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH MI-23 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7D47 | CRYSTAL STRUCTURE OF SARS-COV-2 PAPAIN-LIKE PROTEASE C111S | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7D4F | STRUCTURE OF COVID-19 RNA-DEPENDENT RNA POLYMERASE BOUND TO SURAMIN | 2.7.7.48 3.4.19.12 3.4.22 3.4.22.69 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7D6A | CRYSTAL STRUCTURE OF ORYZA SATIVA OS4BGLU18 MONOLIGNOL BETA-GLUCOSIDASE | 3.2.1.21 |
| 7D6B | CRYSTAL STRUCTURE OF ORYZA SATIVA OS4BGLU18 MONOLIGNOL BETA-GLUCOSIDASE WITH DELTA-GLUCONOLACTONE | 3.2.1.21 |
| 7D6H | CRYSTAL STRUCTURE OF THE SARS-COV-2 PAPAIN-LIKE PROTEASE (PLPRO) C112S MUTANT | 3.4.19.12 3.4.22 3.4.22.69 |
| 7D6N | CRYSTAL STRUCTURE OF TICK-BORNE ENCEPHALITIS VIRUS RNA-DEPENDENT RNA POLYMERASE | 2.7.7.49 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7D7P | CRYSTAL STRUCTURE OF THE PHOSPHODIESTERASE DOMAIN OF SALPINGOECA ROSETTA RHODOPSIN PHOSPHODIESTERASE | 3.1.4 |
| 7D7Q | CRYSTAL STRUCTURE OF THE TRANSMEMBRANE DOMAIN AND LINKER REGION OF SALPINGOECA ROSETTA RHODOPSIN PHOSPHODIESTERASE | 3.1.4 |
| 7D7T | CRYSTAL STRUCTURE OF THE SARS-COV-2 PAPAIN-LIKE PROTEASE (PLPRO) C112S MUTANT BOUND TO COMPOUND S43 | 3.4.19.12 3.4.22 3.4.22.69 |
| 7D7U | CRYSTAL STRUCTURE OF AGO2 MID DOMAIN IN COMPLEX WITH 8-BR-ADENOSIN-5'-MONOPHOSPHATE | 3.1.26 |
| 7D83 | CRYSTAL STRUCTURE OF HIV-1 INTEGRASE CATALYTIC CORE DOMAIN IN COMPLEX WITH 2-(TERT-BUTOXY)-2-(2-(3-CYCLOHEXYLUREIDO)-3,6-DIMETHYL-5-(5-METHYLCHROMAN-6-YL)PYRIDIN-4-YL)ACETIC ACID | 2.7.7 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 3.1 |
| 7D8U | CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF PNP868R FROM AFRICAN SWINE FEVER VIRUS | 2.1.1.56 2.7.7.50 3.1.3.33 |
| 7DDZ | THE CRYSTAL STRUCTURE OF HUMAN NEUROPEPTIDE Y Y2 RECEPTOR WITH JNJ-31020028 | 3.2.1.17 |
| 7DEL | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7DEM | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7DEN | CRYSTAL STRUCTURE OF P.AERUGINOSA LPXC IN COMPLEX WITH INHIBITOR | 3.5.1.108 |
| 7DF4 | SARS-COV-2 S-ACE2 COMPLEX | 3.4.17.23 3.4.17 |
| 7DFM | CRYSTAL STRUCTURE OF GLYCOSIDE HYDROLASE FAMILY 11 BETA-XYLANASE FROM STREPTOMYCES OLIVACEOVIRIDIS E-86 | 3.2.1.8 |
| 7DFN | CRYSTAL STRUCTURE OF GLYCOSIDE HYDROLASE FAMILY 11 BETA-XYLANASE FROM STREPTOMYCES OLIVACEOVIRIDIS E-86 IN COMPLEX WITH ALPHA-L-ARABINOFURANOSYL XYLOTETRAOSE | 3.2.1.8 |
| 7DFO | CRYSTAL STRUCTURE OF GLYCOSIDE HYDROLASE FAMILY 11 BETA-XYLANASE FROM STREPTOMYCES OLIVACEOVIRIDIS E-86 IN COMPLEX WITH 4-O-METHYL-ALPHA-D-GLUCURONOPYRANOSYL XYLOTETRAOSE | 3.2.1.8 |
| 7DFV | CRYO-EM STRUCTURE OF PLANT NLR RPP1 TETRAMER CORE PART | 3.2.2.6 |
| 7DHD | VIBRIO VULNIFICUS WZB | 3.1.3.48 |
| 7DHE | VIBRIO VULNIFICUS WZB IN COMPLEX WITH BENZYLPHOSPHONATE | 3.1.3.48 |
| 7DHF | VIBRIO VULNIFICUS WZB IN COMPLEX WITH BENZYLPHOSPHONATE | 3.1.3.48 |
| 7DIF | GH127 BETA-L-ARABINOFURANOSIDASE HYPBA1 COVALENTLY COMPLEXED WITH BETA-L-ARABINOFURANOSE-CONFIGURED CYCLOPHELLITOL AT 1.75-ANGSTROM RESOLUTION | 3.2.1.185 |
| 7DOO | CRYSTAL STRUCTURE OF PENA BETA-LACTAMASE-AVIBACTAM COMPLEX | 3.5.2.6 |
| 7DR6 | PA28ALPHA-BETA IN COMPLEX WITH IMMUNOPROTEASOME | 3.4.25.1 |
| 7DR7 | BOVINE 20S IMMUNOPROTEASOME | 3.4.25.1 |
| 7DRW | BOVINE 20S IMMUNOPROTEASOME IN COMPLEX WITH TWO HUMAN PA28ALPHA-BETA ACTIVATORS | 3.4.25.1 |
| 7DS7 | THE CRYSTAL STRUCTURE OF LEAF-BRANCH COMPOST CUTINASE FROM BIORTUS. | 3.1.1.74 3.1.1.101 |
| 7DTB | ROOM TEMPEATURE STRUCTURE OF LYSOZYME BY FIXED-TARGET SERIAL CRYSTALLOGRAPHY | 3.2.1.17 |
| 7DTF | ROOM TEMPERATURE STRUCTURE OF LYSOZYME BY SERIAL MILLISECOND CRYSTALLOGRAPHY | 3.2.1.17 |
| 7EST | INTERACTION OF THE PEPTIDE CF3-LEU-ALA-NH-C6H4-CF3(TFLA) WITH PORCINE PANCREATIC ELASTASE. X-RAY STUDIES AT 1.8 ANGSTROMS | 3.4.21.36 |
| 7GCH | STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS | 3.4.21.1 |
| 7GSP | RIBONUCLEASE T1/2',3'-CGPS, NON-PRODUCTIVE | 3.1.27.3 4.6.1.24 |
| 7HVP | X-RAY CRYSTALLOGRAPHIC STRUCTURE OF A COMPLEX BETWEEN A SYNTHETIC PROTEASE OF HUMAN IMMUNODEFICIENCY VIRUS 1 AND A SUBSTRATE-BASED HYDROXYETHYLAMINE INHIBITOR | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 7JFQ | THE CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH DE-OXIDIZED C145 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JHE | ROOM TEMPERATURE STRUCTURE OF SARS-COV-2 NSP10/NSP16 METHYLTRANSFERASE IN A COMPLEX WITH 2'-O-METHYLATED M7GPPPA CAP-1 AND SAH DETERMINED BY FIXED-TARGET SERIAL CRYSTALLOGRAPHY | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7JHP | CRYSTAL STRUCTURE OF HRAS IN COMPLEX WITH THE RAS-BINDING AND CYSTEINE-RICH DOMAINS OF CRAF-KINASE | 3.6.5.2 |
| 7JIB | ROOM TEMPERATURE CRYSTAL STRUCTURE OF NSP10/NSP16 FROM SARS-COV-2 WITH SUBSTRATES AND PRODUCTS OF 2'-O-METHYLATION OF THE CAP-1 | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7JIR | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 , C111S MUTANT, IN COMPLEX WITH PLP_SNYDER457 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JIT | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 , C111S MUTANT, IN COMPLEX WITH PLP_SNYDER495 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JIV | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 , C111S MUTANT, IN COMPLEX WITH PLP_SNYDER530 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JIW | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 IN COMPLEX WITH PLP_SNYDER530 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JKV | CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH AN INHIBITOR GRL-2420 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JL0 | CRYO-EM STRUCTURE OF MDA5-DSRNA IN COMPLEX WITH TRIM65 PSPRY DOMAIN (MONOMER) | 3.6.4.13 |
| 7JL1 | CRYO-EM STRUCTURE OF RIG-I:DSRNA IN COMPLEX WITH RIPLET PRYSPRY DOMAIN (MONOMER) | 3.6.4.13 |
| 7JL2 | CRYO-EM STRUCTURE OF MDA5-DSRNA FILAMENT IN COMPLEX WITH TRIM65 PSPRY DOMAIN (TRIMER) | 3.6.4.13 |
| 7JL3 | CRYO-EM STRUCTURE OF RIG-I:DSRNA FILAMENT IN COMPLEX WITH RIPLET PRYSPRY DOMAIN (TRIMER) | 3.6.4.13 |
| 7JL5 | CRYSTAL STRUCTURE OF HUMAN NEIL3 TANDEM ZINC FINGER GRF DOMAINS | 3.2.2 4.2.99.18 |
| 7JLT | CRYSTAL STRUCTURE OF SARS-COV-2 NSP7-NSP8 COMPLEX. | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JLU | STRUCTURE OF THE ACTIVATED ROQ1 RESISTOSOME DIRECTLY RECOGNIZING THE PATHOGEN EFFECTOR XOPQ | 3.2.2.6 |
| 7JLV | STRUCTURE OF THE ACTIVATED ROQ1 RESISTOSOME DIRECTLY RECOGNIZING THE PATHOGEN EFFECTOR XOPQ | 3.2.2.6 |
| 7JLX | STRUCTURE OF THE ACTIVATED ROQ1 RESISTOSOME DIRECTLY RECOGNIZING THE PATHOGEN EFFECTOR XOPQ (TIR DOMAINS) | 3.2.2.6 |
| 7JME | STRUCTURE OF THE SARS-COV-2 NSP3 MACRO X DOMAIN IN COMPLEX WITH CYCLIC AMP | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JMS | STRUCTURE OF THE HAZARA VIRUS OTU BOUND TO UBIQUITIN | 2.7.7.48 3.4.19.12 |
| 7JMU | HEN EGG-WHITE LYSOZYME WITH IONIC LIQUID ETHYLAMMONIUM NITRATE | 3.2.1.17 |
| 7JN2 | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 IN COMPLEX WITH PLP_SNYDER441 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JNO | X-RAY CRYSTALLOGRAPHIC STRUCTURE OF THE NS3 HELICASE DOMAIN FROM TICK-BORNE ENCEPHALITIS VIRUS | 3.6.4.13 3.4.21.91 3.6.1.15 2.1.1.56 2.1.1.57 2.7.7.48 |
| 7JOY | PRODUCT STRUCTURE OF SARS-COV-2 MPRO C145A MUTANT IN COMPLEX WITH ITS C-TERMINAL AUTOPROCESSING SEQUENCE. | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JP1 | STRUCTURE OF WILD-TYPE SUBSTRATE FREE SARS-COV-2 MPRO. | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JPY | CRYSTAL STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN ITS APO-FORM | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JPZ | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI1 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JQ0 | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI3 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JQ1 | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI4 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JQ2 | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI5 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JQ3 | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI6 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JQ4 | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI7 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JQ5 | STRUCTURE OF THE SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH INHIBITOR MPI8 | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JR3 | SARS-COV-2 3CL PROTEASE CRYSTALLIZED UNDER REDUCING CONDITIONS | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JR4 | SARS-COV-2 3CL PROTEASE WITH ALTERNATIVE CONFORMATION OF THE ACTIVE SITE PROMOTED BY METHYLENE-BRIDGED CYSTEINE AND LYSINE RESIDUES | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JRN | CRYSTAL STRUCTURE OF THE WILD TYPE SARS-COV-2 PAPAIN-LIKE PROTEASE (PLPRO) WITH INHIBITOR GRL0617 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JSN | STRUCTURE OF THE VISUAL SIGNALING COMPLEX BETWEEN TRANSDUCIN AND PHOSPHODIESTERASE 6 | 3.1.4.35 |
| 7JTN | HUMAN COMPLEMENT FACTOR B INHIBITED BY A SLOW OFF-RATE MODIFIED APTAMER OF 29 BASES | 3.4.21.47 |
| 7JTQ | HUMAN COMPLEMENT FACTOR B INHIBITED BY A SLOW OFF-RATE MODIFIED APTAMER OF 31 BASES | 3.4.21.47 |
| 7JTV | STRUCTURE OF IMPA FROM PSEUDOMONAS AERUGINOSA IN COMPLEX WITH AN O-GLYCOPEPTIDE | 3.4.24 |
| 7JU7 | THE CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH MASITINIB | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JUN | JOINT NEUTRON/X-RAY STRUCTURE OF SARS-COV-2 3CL MPRO AT ROOM TEMPERATURE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JV8 | HUMAN CD73 (ECTO 5'-NUCLEOTIDASE) IN COMPLEX WITH COMPOUND 35 | 3.1.3.5 |
| 7JV9 | HUMAN CD73 (ECTO 5'-NUCLEOTIDASE) IN COMPLEX WITH COMPOUND 12 | 3.1.3.5 |
| 7JVM | NON-RECEPTOR PROTEIN TYROSINE PHOSPHATASE SHP2 IN COMPLEX WITH ALLOSTERIC INHIBITOR TNO155 | 3.1.3.48 |
| 7JVN | NON-RECEPTOR PROTEIN TYROSINE PHOSPHATASE SHP2 IN COMPLEX WITH ALLOSTERIC INHIBITOR COMPOUND 24 | 3.1.3.48 |
| 7JVU | CRYSTAL STRUCTURE OF HUMAN HISTONE DEACETYLASE 8 (HDAC8) I45T MUTATION COMPLEXED WITH SAHA | 3.5.1.98 |
| 7JVV | CRYSTAL STRUCTURE OF HUMAN HISTONE DEACETYLASE 8 (HDAC8) E66D/Y306F DOUBLE MUTATION COMPLEXED WITH A TETRAPEPTIDE SUBSTRATE | 3.5.1.98 |
| 7JVW | CRYSTAL STRUCTURE OF HUMAN HISTONE DEACETYLASE 8 (HDAC8) G320R MUTATION COMPLEXED WITH M344 | 3.5.1.98 |
| 7JVZ | SARS COV-2 MAIN PROTEASE 3CLPRO, ROOM TEMPERATURE, DAMAGE FREE XFEL MONOCLINIC STRUCTURE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JW2 | CRYSTAL STRUCTURE OF AEDES AEGYPTI NIBBLER EXO DOMAIN | 3.1 |
| 7JW6 | CRYSTAL STRUCTURE OF DROSOPHILA NIBBLER EXO DOMAIN | 3.1 |
| 7JY5 | STRUCTURE OF HUMAN P97 IN COMPLEX WITH ATPGAMMAS AND NPL4/UFD1 (MASKED AROUND P97) | 3.6.4.6 |
| 7JYC | CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE (3CLPRO/MPRO) IN COMPLEX WITH COVALENT INHIBITOR NARLAPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7JYI | SUBPARTICLE MAP OF ZIKV MR-766 | 3.4.21.91 3.6.1.15 3.6.4.13 2.1.1.56 2.1.1.57 2.7.7.48 |
| 7JYY | CRYSTAL STRUCTURE OF SARS-COV-2 NSP16/10 HETERODIMER IN COMPLEX WITH (M7GPPPA)PUPUPAPAPA (CAP-0) AND S-ADENOSYLMETHIONINE (SAM). | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7JZ0 | CRYSTAL STRUCTURE OF SARS-COV-2 NSP16/10 HETERODIMER IN COMPLEX WITH (M7GPPPA2M)PUPUPAPAPA (CAP-1) AND S-ADENOSYL-L-HOMOCYSTEINE (SAH). | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7K0F | 1.65 A RESOLUTION STRUCTURE OF SARS-COV-2 3CL PROTEASE IN COMPLEX WITH A DEUTERATED GC376 ALPHA-KETOAMIDE ANALOG (COMPOUND 5) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K0R | NUCLEOTIDE BOUND SARS-COV-2 NSP15 | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 7K0W | THE CRYSTAL STRUCTURE OF THE 2009/H1N1/CALIFORNIA PA ENDONUCLEASE (CONSTRUCT WITH TRUNCATED LOOP 51-72) IN COMPLEX WITH BALOXAVIR ACID | 3.1 |
| 7K1L | CRYSTAL STRUCTURE OF NSP15 ENDORIBONUCLEASE FROM SARS COV-2 IN THE COMPLEX WITH URIDINE-2',3'-VANADATE | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 7K1V | PARTIAL OPEN STATE OF MYCOBACTERIUM TUBERCULOSIS ZINC METALLOPROTEASE 1 | 3.4.24 |
| 7K1W | PIKFYVE/FIG4/VAC14 COMPLEX CENTERED ON FIG4 - MAP3 | 3.1.3 |
| 7K2W | CRYSTAL STRUCTURE OF CTX-M-14 E166A/K234R BETA-LACTAMASE IN COMPLEX WITH HYDROLYZED CEFOTAXIME | 3.5.2.6 |
| 7K2X | CRYSTAL STRUCTURE OF CTX-M-14 E166A/K234R BETA-LACTAMASE | 3.5.2.6 |
| 7K2Y | CRYSTAL STRUCTURE OF CTX-M-14 E166A/K234R BETA-LACTAMASE IN COMPLEX WITH HYDROLYZED AMPICILLIN | 3.5.2.6 |
| 7K3M | CRYSTAL STRUCTURE OF THE BETA LACTAMASE CLASS D FROM CHITINOPHAGA PINENSIS BY SERIAL CRYSTALLOGRAPHY | 3.5.2.6 |
| 7K3N | CRYSTAL STRUCTURE OF NSP1 FROM SARS-COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K3T | CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE (3CLPRO/MPRO) IN THE APO FORM AT 1.2 A RESOLUTION | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K40 | CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE (3CLPRO/MPRO) IN COMPLEX WITH COVALENT INHIBITOR BOCEPREVIR AT 1.35 A RESOLUTION | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K41 | BACTERIAL O-GLCNACASE (OGA) WITH COMPOUND | 3.2.1.169 |
| 7K4P | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3 | 3.2.1.8 |
| 7K4Q | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3 IN COMPLEX WITH THE TRANSITION STATE ANALOG 6-NITROBENZOTRIAZOLE | 3.2.1.8 |
| 7K4R | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3 K50Q | 3.2.1.8 |
| 7K4S | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.7 | 3.2.1.8 |
| 7K4T | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.17 | 3.2.1.8 |
| 7K4U | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3 K50Q IN COMPLEX WITH THE TRANSITION STATE ANALOG 6-NITROBENZOTRIAZOLE | 3.2.1.8 |
| 7K4V | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.17 | 3.2.1.8 |
| 7K4W | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.17 IN THE INACTIVE STATE | 3.2.1.8 |
| 7K4X | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.7 IN COMPLEX WITH THE TRANSITION STATE ANALOG 6-NITROBENZOTRIAZOLE | 3.2.1.8 |
| 7K4Z | CRYSTAL STRUCTURE OF KEMP ELIMINASE HG3.17 IN COMPLEX WITH THE TRANSITION STATE ANALOG 6-NITROBENZOTRIAZOLE | 3.2.1.8 |
| 7K5I | SARS-COV-2 NSP1 IN COMPLEX WITH HUMAN 40S RIBOSOME | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K5K | PLASMODIUM VIVAX M17 LEUCYL AMINOPEPTIDASE PV-M17 | 3.4.11.1 |
| 7K5W | CRYO-EM STRUCTURE OF HETEROLOGOUS PROTEIN COMPLEX LOADED THERMOTOGA MARITIMA ENCAPSULIN CAPSID | 3.4 |
| 7K6D | SARS-COV-2 MAIN PROTEASE CO-CRYSTAL STRUCTURE WITH TELAPREVIR DETERMINED FROM CRYSTALS GROWN WITH 40 NL ACOUSTICALLY EJECTED MPRO DROPLETS AT 1.48 A RESOLUTION (CRYO-PROTECTED) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K6E | SARS-COV-2 MAIN PROTEASE CO-CRYSTAL STRUCTURE WITH TELAPREVIR DETERMINED FROM CRYSTALS GROWN WITH 40 NL ACOUSTICALLY EJECTED MPRO DROPLETS AT 1.63 A RESOLUTION (DIRECT VITRIFICATION) | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K74 | CRYSTAL STRUCTURE OF FRUCTOSE-1,6-BISPHOSPHATASE, TYPE I, FROM STENOTROPHOMONAS MALTOPHILIA K279A | 3.1.3.11 |
| 7K7P | STRUCTURE OF SARS-COV-2 NONSTUCTURAL PROTEIN 1 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7K7Y | CRYSTAL STRUCTURE OF BONT/E LC-HN DOMAIN IN COMPLEX WITH VHH JLE-E9 | 3.4.24.69 |
| 7K84 | CRYSTAL STRUCTURE OF BONT/E LC-HN DOMAIN IN COMPLEX WITH VHH JLE-E5 | 3.4.24.69 |
| 7K93 | DENV2 NS1 IN COMPLEX WITH NEUTRALIZING 2B7 SINGLE CHAIN FAB VARIABLE REGION (SCFV) | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7K99 | CRYSTAL STRUCTURE OF P. AERUGINOSA LPXC WITH N-HYDROXYFORMAMIDE INHIBITOR 19 | 3.5.1.108 |
| 7K9A | CRYSTAL STRUCTURE OF P. AERUGINOSA LPXC WITH N-HYDROXYFORMAMIDE INHIBITOR | 3.5.1.108 |
| 7KAG | CRYSTAL STRUCTURE OF THE UBIQUITIN-LIKE DOMAIN 1 (UBL1) OF NSP3 FROM SARS-COV-2 | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KBG | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH A 2-SUBSTITUTED BENZAMIDE INHIBITOR (COMPOUND 20) | 3.5.1.98 |
| 7KBH | STRUCTURE OF HUMAN HDAC2 IN COMPLEX WITH A 2-SUBSTITUTED BENZAMIDE INHIBITOR (COMPOUND 16) | 3.5.1.98 |
| 7KCR | CRYO-EM STRUCTURE OF ZIKA VIRUS IN COMPLEX WITH E PROTEIN CROSS-LINKING HUMAN MONOCLONAL ANTIBODY ADI30056 | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7KEG | CRYSTAL STRUCTURE FROM SARS-COV2 NENDOU NSP15 | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 7KEP | AVIBACTAM-CDD-1 2 MINUTE COMPLEX | 3.5.2.6 |
| 7KEQ | AVIBACTAM-CDD-1 6 MINUTE COMPLEX | 3.5.2.6 |
| 7KER | AVIBACTAM-CDD-1 45 MINUTE COMPLEX | 3.5.2.6 |
| 7KF4 | CRYSTAL STRUCTURE FROM SARS-COV-2 NENDOU NSP15 | 3.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 2.1.1 |
| 7KFI | SARS-COV-2 MAIN PROTEASE IMMATURE FORM - APO STRUCTURE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KG3 | CRYSTAL STRUCTURE OF COV-2 NSP3 MACRODOMAIN | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KHP | ACYL-ENZYME INTERMEDIATE STRUCTURE OF SARS-COV-2 MPRO IN COMPLEX WITH ITS C-TERMINAL AUTOPROCESSING SEQUENCE. | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KHS | OGOGA IN COMPLEX WITH LIGAND 55 | 3.2.1.169 |
| 7KHV | CPOGA IN COMPLEX WITH LIGAND 54 | 3.2.1.169 |
| 7KIO | CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE (INPP1) D54A MUTANT | 3.1.3.57 |
| 7KIR | CRYSTAL STRUCTURE OF INOSITOL POLYPHOSPHATE 1-PHOSPHATASE (INPP1) D54A MUTANT IN COMPLEX WITH INOSITOL (1,4)-BISPHOSPHATE | 3.1.3.57 |
| 7KIS | CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA PBP2 IN COMPLEX WITH WCK 5153 | 3.4.16.4 |
| 7KIT | CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA PBP3 IN COMPLEX WITH WCK 4234 | 3.4.16.4 |
| 7KIV | CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA PBP3 IN COMPLEX WITH AVIBACTAM | 3.4.16.4 |
| 7KIW | CRYSTAL STRUCTURE OF PSEUDOMONAS AERUGINOSA PBP3 IN COMPLEX WITH ZIDEBACTAM | 3.4.16.4 |
| 7KMB | ACE2-RBD FOCUSED REFINEMENT USING SYMMETRY EXPANSION OF APPLIED C3 FOR TRIPLE ACE2-BOUND SARS-COV-2 TRIMER SPIKE AT PH 7.4 | 3.4.17.23 3.4.17 |
| 7KME | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711. | 3.4.21.5 |
| 7KOA | ROOM TEMPERATURE STRUCTURE OF SARS-COV-2 NSP10/16 METHYLTRANSFERASE IN A COMPLEX WITH CAP-0 AND SAM DETERMINED BY PINK-BEAM SERIAL CRYSTALLOGRAPHY | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7KOJ | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2, C111S MUTANT, IN COMPLEX WITH PLP_SNYDER494 | 3.4.19.12 3.4.22 3.4.22.69 |
| 7KOK | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2, C111S MUTANT, IN COMPLEX WITH PLP_SNYDER496 | 3.4.19.12 3.4.22 3.4.22.69 |
| 7KOL | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2 IN COMPLEX WITH PLP_SNYDER496 | 3.4.19.12 3.4.22 3.4.22.69 |
| 7KPH | SARS-COV-2 MAIN PROTEASE IN MATURE FORM | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KQO | CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN (P43 CRYSTAL FORM) | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KQP | CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN IN COMPLEX WITH ADP-RIBOSE (P43 CRYSTAL FORM) | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KQW | CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN (C2 CRYSTAL FORM, METHYLATED) | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KR0 | CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN (C2 CRYSTAL FORM, 100 K) | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KR1 | CRYSTAL STRUCTURE OF SARS-COV-2 NSP3 MACRODOMAIN (C2 CRYSTAL FORM, 310 K) | 3.4.22 3.4.19.12 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KRC | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH (E)-4-(3-CHLORO-5-(2-CYANOVINYL)PHENOXY)-3-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENYL SULFUROFLUORIDATE (JLJ709) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 7KRD | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 4-(3-CHLORO-5-CYANOPHENOXY)-3-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENYL SULFUROFLUORIDATE (JLJ702) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 7KRE | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH 4-((6-CYANONAPHTHALEN-1-YL)OXY)-3-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENYL SULFUROFLUORIDATE (JLJ704) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 7KRF | CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH (E)-4-(3-(2-CYANOVINYL)-5-FLUOROPHENOXY)-3-(2-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)ETHOXY)PHENYL SULFUROFLUORIDATE (JLJ710) | 2.7.7.49 2.7.7.7 3.1.26.13 3.4.23.16 3.1.13.2 2.7.7 3.1 |
| 7KRX | THE CRYSTAL STRUCTURE OF PAPAIN-LIKE PROTEASE OF SARS COV-2, C111S MUTANT, IN COMPLEX WITH PLP_SNYDER441 | 3.4.19.12 3.4.22 3.4.22.69 |
| 7KSL | SUBSTRATE-FREE HUMAN MITOCHONDRIAL LONP1 | 3.4.21.53 |
| 7KSM | HUMAN MITOCHONDRIAL LONP1 WITH ENDOGENOUS SUBSTRATE | 3.4.21.53 |
| 7KV8 | CHIMERIC FLAVIVIRUS BETWEEN BINJARI VIRUS AND DENGUE VIRUS SEROTYPE-2 | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7KV9 | CHIMERIC FLAVIVIRUS BETWEEN BINJARI VIRUS AND WEST NILE (KUNJIN) VIRUS | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7KVA | STRUCTURE OF WEST NILE VIRUS (KUNJIN) | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7KVB | CHIMERIC FLAVIVIRUS BETWEEN BINJARI VIRUS AND MURRAY VALLEY ENCEPHALITIS VIRUS | 3.4.21.91 3.6.1.15 3.6.4.13 |
| 7KVG | SARS-COV-2 MAIN PROTEASE C145S MUTANT IN COMPLEX WITH N AND C-TERMINAL RESIDUES | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KVL | SARS-COV-2 MAIN PROTEASE IMMATURE FORM - FMAX LIBRARY E01 FRAGMENT | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KVR | SARS-COV-2 MAIN PROTEASE IMMATURE FORM - FMAX LIBRARY E09 FRAGMENT | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KX5 | CRYSTAL STRUCTURE OF THE SARS-COV-2 (COVID-19) MAIN PROTEASE IN COMPLEX WITH NONCOVALENT INHIBITOR JUN8-76-3A | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KYU | THE CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE WITH THE FORMATION OF CYS145-1H-INDOLE-5-CARBOXYLATE | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7KZ7 | CRYSTALS STRUCTURE OF THE MUTATED PROTEASE DOMAIN OF BOTULINUM NEUROTOXIN X (X4130B1). | 3.4.24.69 |
| 7L0A | CRYSTAL STRUCTURE OF S-FORMYLGLUTATHIONE HYDROLASE (FRMB) FROM STAPHYLOCOCCUS AUREUS, APOENZYME | 3.1.2.12 |
| 7L0B | CRYSTAL STRUCTURE OF HYDROXYACYL GLUTATHIONE HYDROLASE (GLOB) FROM STAPHYLOCOCCUS AUREUS, APOENZYME | 3.1.2.6 3 |
| 7L52 | CRYSTAL STRUCTURE OF THE METALLO BETA LACTAMASE L1 FROM STENOTROPHOMONAS MALTOPHILIA DETERMINED BY SERIAL CRYSTALLOGRAPHY | 3.5.2.6 |
| 7L5D | THE CRYSTAL STRUCTURE OF SARS-COV-2 MAIN PROTEASE IN COMPLEX WITH DEMETHYLATED ANALOG OF MASITINIB | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7L6R | CRYSTAL STRUCTURE OF SARS-COV-2 NSP16/10 HETERODIMER IN COMPLEX WITH (M7GPPPA2M)PUPUPAPAPA (CAP-1), S-ADENOSYL-L-HOMOCYSTEINE (SAH) AND MANGANESE (MN). | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7L6T | CRYSTAL STRUCTURE OF SARS-COV-2 NSP16/10 HETERODIMER IN COMPLEX WITH (M7GPPPA2M)PUPUPAPAPA (CAP-1), S-ADENOSYL-L-HOMOCYSTEINE (SAH) AND TWO MAGNESIUM (MG) IONS. | 2.1.1 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 |
| 7L84 | HEN EGG WHITE LYSOZYME BY NATIVE S-SAD AT ROOM TEMPERATURE | 3.2.1.17 |
| 7LB7 | JOINT X-RAY/NEUTRON STRUCTURE OF SARS-COV-2 MAIN PROTEASE (3CL MPRO) IN COMPLEX WITH TELAPREVIR | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7LDX | SARS-COV-2 MAIN PROTEASE IMMATURE FORM - F2X ENTRY LIBRARY E06 FRAGMENT | 3.4.22.69 3.4.19.12 3.4.22 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7LGO | CRYSTAL STRUCTURE OF THE NUCLEIC ACID BINDING DOMAIN (NAB) OF NSP3 FROM SARS-COV-2 | 3.4.19.12 3.4.22 3.4.22.69 2.7.7.48 3.6.4.12 3.6.4.13 3.1.13 3.1 2.1.1 |
| 7LGP | DAPE ENZYME FROM SHIGELLA FLEXNERI | 3.5.1.18 |
| 7LPR | STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS | 3.4.21.12 |
| 7LYZ | PROTEIN MODEL BUILDING BY THE USE OF A CONSTRAINED-RESTRAINED LEAST-SQUARES PROCEDURE | 3.2.1.17 |
| 7LZM | COMPARISON OF THE CRYSTAL STRUCTURE OF BACTERIOPHAGE T4 LYSOZYME AT LOW, MEDIUM, AND HIGH IONIC STRENGTHS | 3.2.1.17 |
| 7NN9 | NATIVE INFLUENZA VIRUS NEURAMINIDASE SUBTYPE N9 (TERN) | 3.2.1.18 |
| 7PCK | CRYSTAL STRUCTURE OF WILD TYPE HUMAN PROCATHEPSIN K | 3.4.22.38 |
| 7PTD | PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C MUTANT R163K | 3.1.4.10 4.6.1.13 |
| 7RAT | EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K | 3.1.27.5 4.6.1.18 |
| 7RNT | CRYSTAL STRUCTURE OF THE TYR45TRP MUTANT OF RIBONUCLEASE T1 IN A COMPLEX WITH 2'-ADENYLIC ACID | 3.1.27.3 4.6.1.24 |
| 7RSA | STRUCTURE OF PHOSPHATE-FREE RIBONUCLEASE A REFINED AT 1.26 ANGSTROMS | 3.1.27.5 4.6.1.18 |
| 7TAA | FAMILY 13 ALPHA AMYLASE IN COMPLEX WITH ACARBOSE | 3.2.1.1 |
| 7TLI | THERMOLYSIN (90% ISOPROPANOL SOAKED CRYSTALS) | 3.4.24.27 |
| 7TLN | STRUCTURAL ANALYSIS OF THE INHIBITION OF THERMOLYSIN BY AN ACTIVE-SITE-DIRECTED IRREVERSIBLE INHIBITOR | 3.4.24.27 |
| 7UPJ | HIV-1 PROTEASE/U101935 COMPLEX | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 821P | THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLYCINE-12 MUTANT OF P21H-RAS | 3.6.5.2 |
| 830C | COLLAGENASE-3 (MMP-13) COMPLEXED TO A SULPHONE-BASED HYDROXAMIC ACID | 3.4.24 |
| 8A3H | CELLOBIOSE-DERIVED IMIDAZOLE COMPLEX OF THE ENDOGLUCANASE CEL5A FROM BACILLUS AGARADHAERENS AT 0.97 A RESOLUTION | 3.2.1.4 |
| 8CPA | COMPARISON OF THE STRUCTURES OF THREE CARBOXYPEPTIDASE A-PHOSPHONATE COMPLEXES DETERMINED BY X-RAY CRYSTALLOGRAPHY | 3.4.17.1 |
| 8EST | REACTION OF PORCINE PANCREATIC ELASTASE WITH 7-SUBSTITUTED 3-ALKOXY-4-CHLOROISOCOUMARINS: DESIGN OF POTENT INHIBITORS USING THE CRYSTAL STRUCTURE OF THE COMPLEX FORMED WITH 4-CHLORO-3-ETHOXY-7-GUANIDINO-ISOCOUMARIN | 3.4.21.36 |
| 8HVP | STRUCTURE AT 2.5-ANGSTROMS RESOLUTION OF CHEMICALLY SYNTHESIZED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE COMPLEXED WITH A HYDROXYETHYLENE*-BASED INHIBITOR | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 8KME | CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770. | 3.4.21.5 |
| 8LPR | STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS | 3.4.21.12 |
| 8LYZ | AN X-RAY STUDY OF THE STRUCTURE AND BINDING PROPERTIES OF IODINE-INACTIVATED LYSOZYME | 3.2.1.17 |
| 8OHM | CRYSTAL STRUCTURE OF RNA HELICASE FROM GENOTYPE 1B HEPATITIS C VIRUS: MECHANISM OF UNWINDING DUPLEX RNA | 3.4.22 3.4.21.98 3.6.1.15 3.6.4.13 2.7.7.48 |
| 8PCH | CRYSTAL STRUCTURE OF PORCINE CATHEPSIN H DETERMINED AT 2.1 ANGSTROM RESOLUTION: LOCATION OF THE MINI-CHAIN C-TERMINAL CARBOXYL GROUP DEFINES CATHEPSIN H AMINOPEPTIDASE FUNCTION | 3.4.22.16 |
| 8PRK | THE R78K AND D117E ACTIVE SITE VARIANTS OF SACCHAROMYCES CEREVISIAE SOLUBLE INORGANIC PYROPHOSPHATASE: STRUCTURAL STUDIES AND MECHANISTIC IMPLICATIONS | 3.6.1.1 |
| 8RAT | EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K | 3.1.27.5 4.6.1.18 |
| 8RNT | STRUCTURE OF RIBONUCLEASE T1 COMPLEXED WITH ZINC(II) AT 1.8 ANGSTROMS RESOLUTION: A ZN2+.6H2O.CARBOXYLATE CLATHRATE | 3.1.27.3 4.6.1.24 |
| 8RSA | CRYSTAL STRUCTURE OF TWO COVALENT NUCLEOSIDE DERIVATIVES OF RIBONUCLEASE A | 3.1.27.5 4.6.1.18 |
| 8TLI | THERMOLYSIN (100% ISOPROPANOL SOAKED CRYSTALS) | 3.4.24.27 |
| 8TLN | STRUCTURAL COMPARISON SUGGESTS THAT THERMOLYSIN AND RELATED NEUTRAL PROTEASES UNDERGO HINGE-BENDING MOTION DURING CATALYSIS | 3.4.24.27 |
| 966C | CRYSTAL STRUCTURE OF FIBROBLAST COLLAGENASE-1 COMPLEXED TO A DIPHENYL-ETHER SULPHONE BASED HYDROXAMIC ACID | 3.4.24 3.4.24.7 |
| 9EST | STRUCTURAL STUDY OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH 7-AMINO-3-(2-BROMOETHOXY)-4-CHLOROISOCOUMARIN AS A NONREACTIVATABLE DOUBLY COVALENT ENZYME-INHIBITOR COMPLEX | 3.4.21.36 |
| 9GAA | PRECURSOR OF THE T152A MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM | 3.5.1.26 |
| 9GAC | PRECURSOR OF THE T152C MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM | 3.5.1.26 |
| 9GAF | PRECURSOR OF THE W11F MUTANT GLYCOSYLASPARAGINASE FROM FLAVOBACTERIUM MENINGOSEPTICUM | 3.5.1.26 |
| 9HVP | DESIGN, ACTIVITY AND 2.8 ANGSTROMS CRYSTAL STRUCTURE OF A C2 SYMMETRIC INHIBITOR COMPLEXED TO HIV-1 PROTEASE | 3.4.23.16 2.7.7.49 2.7.7.7 3.1.26.13 3.1.13.2 2.7.7 3.1 |
| 9LPR | STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS | 3.4.21.12 |
| 9LYZ | X-RAY CRYSTALLOGRAPHY OF THE BINDING OF THE BACTERIAL CELL WALL TRISACCHARIDE NAM-NAG-NAM TO LYSOZYME | 3.2.1.17 |
| 9PAP | STRUCTURE OF PAPAIN REFINED AT 1.65 ANGSTROMS RESOLUTION | 3.4.22.2 |
| 9RAT | EFFECTS OF TEMPERATURE ON PROTEIN STRUCTURE AND DYNAMICS: X-RAY CRYSTALLOGRAPHIC STUDIES OF THE PROTEIN RIBONUCLEASE-A AT NINE DIFFERENT TEMPERATURES FROM 98 TO 320 K | 3.1.27.5 4.6.1.18 |
| 9RNT | RIBONUCLEASE T1 WITH FREE RECOGNITION AND CATALYTIC SITE: CRYSTAL STRUCTURE ANALYSIS AT 1.5 ANGSTROMS RESOLUTION | 3.1.27.3 4.6.1.24 |
| 9RSA | CRYSTAL STRUCTURE OF TWO COVALENT NUCLEOSIDE DERIVATIVES OF RIBONUCLEASE A | 3.1.27.5 4.6.1.18 |
